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ABSTRACT
Carbonylated (oxidized) proteins are known to accumulate in the brain of
patients with multiple sclerosis (MS) and in the spinal cord of rats with acute
experimental autoimmune encephalomyelitis (EAE). Yet, our knowledge
regarding mechanism(s) underlying the build-up of protein carbonyls in these
inflammatory demyelinating disorders is quite limited. The objectives of this
dissertation were (1) to measure the changes in protein carbonylation during
disease progression, and to identify the target cells and modified proteins in the
cerebellum of EAE animals, prepared by active immunization of C57/BL6 mice
with MOG35-55 peptide, (2) to determine if the accumulation of carbonylated
proteins in the CNS of these animals is due to a defect in the degradation of the
modified proteins and (3) to establish if a similar mechanism underlies the buildup of carbonylated proteins in the cerebral white matter (WM) and gray matter
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(GM) of MS patients. Initial studies using double immunofluorescence
microscopy showed that carbonyls accumulate mostly in white matter astrocytes
of EAE mice, both in the acute and chronic phase. Two-dimensional oxyblot and
mass spectrometry analysis identified β-actin, β-tubulin, GFAP and HSC-71 as
the major carbonylation species throughout disease. Using a pull-down/western
blot method I also discovered that the proportion of carbonylated cytoskeletal
proteins is elevated in chronic EAE, suggesting that as disease progresses from
the inflammatory to the neurodegenerative phase there may be an inappropriate
removal of these species. This idea was subsequently tested by identifying the
20S proteasome as the proteolytic system responsible for the elimination of
oxidized cytoskeletal proteins in cultured astrocytes and by demonstrating that
the proteasomal activities were reduced in chronic EAE. These findings were
finally extended to the human disease, where I found a profound decrease in
proteasomal activity both in the normal-appearing GM and WM of MS patients.
Collectively, the studies presented in this dissertation demonstrate that an
impaired 20S proteasome in the central nervous system of chronic EAE mice and
MS patients significantly contributes to the accumulation of carbonylated (and
potentially toxic) proteins. This work may provide the foundation for future studies
aimed at developing new approaches to treat MS.
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1. General Introduction
1.1 Multiple Sclerosis and its animal model experimental autoimmune
encephalomyelitis (EAE)
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the
central nervous system (CNS) affecting approximately 1 in 700 young adults, and
thereby representing a major burden for their families and communities in North
America and Europe (Trapp and Syts, 2009). The pathological changes that
contribute to neurological disability in MS include inflammation, demyelination,
gliosis, oligodendrocyte death and axonal degeneration (Kornek and Lassmann,
1999). In most patients, MS presents as a biphasic disease characterized initially
by remittent, acute neurological dysfunction followed by a progressive increase in
disability (Gonsette, 2008). It is believed that different pathological mechanisms
take place in the relapsing-remitting (RR) and in the secondary progressive (SP)
stages; the RR phase being associated with transient, immune mediated
inflammatory reactions and the SP phase with steady, neurodegenerative
processes (Gonsette, 2008).
Experimental autoimmune (allergic) encephalomyelitis (EAE) recapitulates
a number of clinical and pathological features of MS, and is routinely employed to
study the mechanistic bases of disease and to test therapeutic approaches (Gold
et al., 2000). EAE can be induced in a variety of mammalian species by active
immunization with myelin-specific antigens or by adoptive transfer of T-cells from
immunized animals into naïve recipients. Depending on the nature of the
autoantigen and the strain of the animals utilized, EAE can be made acute,
1

chronic monophasic or chronic relapsing, to model the course of the
experimental disorder to the various types of MS. The studies in this thesis
employed the chronic monophasic EAE model in female C57BL/6 mice produced
by active immunization with myelin oligodendrocyte glycoprotein (MOG) peptide
139-151. This animal model is characterized by acute inflammation (without
demyelination) throughout the CNS at the peak of disease and by
neurodegeneration (extensive demyelination and axonal damage with minor
inflammation) during the chronic phase (Kuerten et al., 2007). These features
make this an ideal model to study the pathophysiological mechanisms underlying
disease progression.
1.2 Oxidative stress and protein carbonylation in MS/EAE
1.2.1 Oxidative stress plays a major role in the pathogenesis of MS/EAE and
protein carbonylation is one of the most significant chemical modification
from severe and/or prolonged oxidative stress.
Oxidative stress (OS) is a condition in which the cellular antioxidant
defenses are insufficient to keep the levels of reactive oxygen species (ROS)
below a toxic threshold (Mancuso et al., 2009). Clearly, OS may be induced by
increased ROS, decreased antioxidant defenses or both. During the course of
MS and EAE, an excessive amount of several ROS including hydrogen peroxide
(H2O2), superoxide (O2.-), hypochlorous acid (HClO) and peroxynitrite (ONOO-)
are extracellularly and intracellularly generated in the CNS (Bizzozero, 2009).
The major ROS produced extracellularly come from infiltrating phagocytes and
activated microglia while intracellular ROS (mostly O2.- and H2O2) are largely
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produced by dysfunctional mitochondria, which may result from glutamate
excitotoxicity, axonal depolarization, and glutathione depletion (Bizzozero, 2009).
In addition, cellular antioxidant defense systems in MS are weakened as inferred
from (1) reduced plasma levels of antioxidants (e.g. ubiquinone, vitamin E) and
antioxidant enzymes (e.g. catalase and glutathione peroxidase), and (2) low
levels of antioxidants like glutathione, α-tocopherol and uric acid in MS plaques
(Bizzozero, 2009). Furthermore, various antioxidant treatments including Nacetylcysteine, bilirubin, uric acid and catalase, were found to be effective on
ameliorating EAE (Bizzozero, 2009). Together the above studies suggest that
oxidative stress plays a major role in the development of tissue injury in MS/EAE.
More specifically, oxidative stress has been implicated as a mediator of
demyelination and axonal damage in MS and EAE (Gilgun-sherki et al., 2004).
The principal outcome of oxidative stress is the chemical transformation of
lipid, proteins, and nucleic acid by ROS. Among these, protein carbonylation is
one of the most significant chemical modifications (Bizzozero, 2009), due to the
high susceptibility of most amino acids to oxidation and its irreversible nature.
Carbonylation affects the biological activity of important structural and enzymatic
polypeptides. For example, carbonylation of tubulin can lead to microtubule
disassembly and instability, while actin filaments are also easily depolymerized
upon carbonylation (Yan and Sohal, 1998). Thus, protein carbonyls (PCOs) are
likely to play an important role in the pathophysiology of disorders in which there
is considerable OS, such as in neurodegenerative and chronic inflammatory
diseases (Bizzozero, 2009).
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1.2.2 Direct oxidation by ROS is the major process for producing protein
carbonyls in glutathione-depleted rat brain slices and EAE cerebellum
Carbonyl groups are introduced into proteins by two different mechanisms
(Figure 1.1). The first one involves the direct metal ion-catalyzed oxidation of
side-chains of proline, arginine, lysine, and threonine through Fenton chemistry.
A small portion of the protein carbonyls may also arise from decomposition of
side-chain hydroperoxides of Val and Leu. The second mechanism involves the
reaction of the nucleophilic centers in cysteine, histidine, or lysine residues with
reactive carbonyl species (RCS) derived from the oxidation of lipids [e.g., 4hydroxynonenal (4-HNE), malondialdehyde (MDA), acrolein (ACR)], and
carbohydrates [(e.g., glyoxal (GO), methylglyoxal (MGO)] (Bizzozero, 2009).
These non-oxidative processes of carbonyl formation are termed lipoxidation and
glycoxidation, respectively. Despite of much work done in this field, there is still
controversy as to the relative contribution of oxidative (direct) and non-oxidative
(indirect) pathways to the total amount of carbonyls present in a protein. While
directly oxidized amino acids have been found as the major modified species in
rat liver and human brain proteins, inhibition of lipid peroxidation (indirect
pathway) is also known to reduce protein carbonyls in diseased tissues. To
identify the major pathway of carbonylation with the goal to provide possible
therapeutic strategies by preventing it, I used glutathione-depleted rat brain slices.
Acute depletion of GSH, accomplished with dimethyl maleate (DEM), significantly
increases mitochondrial production of superoxide and hydrogen peroxide (Zheng
and Bizzozero, 2009), leading to oxidative stress. Interestingly, RCS including 4-
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HNE, MDA and ACR were barely detectable in these tissues and traditional RCS
scavengers failed to prevent the carbonylation of brain proteins. These findings
clearly suggest that the direct oxidation by ROS, is the major process in this
paradigm (see appendix A). More importantly, RCS were also barely detectable
in EAE tissues, indicating that lipoxidation and glycoxidation are unlikely to
produce protein carbonyls in inflammatory demyelinating diseases (see chapter
2).

Figure 1.1 Mechanisms of formation of protein-bound carbonyls. (From Bizzozero O.A.,
Protein carbonylation in neurodegenerative and demyelinating CNS disease. Handbook
of neurochemistry and Molecular Neurobiology. 2009. pp, 543-562)
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1.2.3 Protein carbonyls accumulate in MS/EAE CNS tissue
Accumulation of protein carbonyls has been implicated in the etiology
and/or progression of several neurodegenerative disorders such as Alzheimer’s
disease (Aksenov et al., 2001), Parkinson’s disease (Floor and Wetzel 1998),
and amyotrophic lateral sclerosis (Ferrante et al., 1997). Our lab recently showed
that protein carbonyls also accumulate in the brain of patients with multiple
sclerosis (MS) (Bizzozero et al., 2005) and in the spinal cord of rats with acute
experimental autoimmune encephalomyelitis (EAE) (Smerjac and Bizzozero,
2008), suggesting that this type of chemical modification may play a critical
pathophysiological role in inflammatory demyelinating diseases as well. However,
little efforts have been devoted util now to investigate protein carbonyl
accumulation during disease progression in EAE. The primary targets of
oxidative stress can vary depending on the cell type, the absolute level and the
half-life of the oxidant produced, the chemical nature and site of ROS generation
(intra- vs. extra-cellular), and the proximity of the oxidant to a specific cellular
substrate (Dalle-Donne, 2006). Consequently, my work was initially geared to
identify the target cells and the modified proteins in the cerebellum of animals
during the acute and chronic phases of EAE. As described in chapter 2, β-actin,
β-tubulin, glial fibrillary acidic protein (GFAP) and heat shock cognate-71 (HSC71) were identified as the major targets of carbonylation, and most of the
carbonyls were found inside astrocytes in both phases of EAE animals. Moreover,
I observed that as disease progresses the proportion of the carbonylated forms
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of the cytoskeletal proteins including β-actin, β-tubulin and GFAP was notably
increased.
1.3 Possible mechanisms underlying the accumulation of carbonylated
cytoskeletal proteins inside cerebellar astrocytes in chronic EAE
The level of oxidized proteins is determined by rates of generation and
degradation of carbonyls, as well as the addition of newly synthesized
macromolecules (Figure 1.2). Currently, proteolytic degradation is considered to
be the only physiological mechanism for elimination of carbonylated proteins
since there is no evidence for enzymatic reduction of protein-bound carbonyls to
alcohols (Bizzozero, 2008). Therefore, since protein carbonyls cannot be
repaired and since there is less oxidative stress in chronic than in acute EAE
(Zheng and Bizzozero, 2010), it is fair to propose that the accumulation of
carbonylated cytoskeletal proteins in cerebellum of chronic EAE mice may be
due to their impaired degradation. The build-up of carbonylated cytoskeletal
proteins could be caused by reduced activity of the degradation system and/or by
decreased susceptibility of the oxidized proteins to proteolysis.
In order to maintain homeostasis, all cells must continually degrade proteins
in an efficient and reliable manner (Figure 1.2). Mammalian cells contain four
major proteolytic systems including the cathepsins inside lysosomes, the
mitochondrial Lon protease, the calpains and the 20S/26S proteasomes, the
latter localized in the cytosol, nuclei, and endoplasmic reticulum (Grune, 2001).
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Figure 1.2 Protein oxidative modifications and maintenance systems. (Adapted from
Farout and Friguet (2006) Proteasome function in aging and oxidative stress:
implications in protein maintenance failure. Antioxidants & redox signaling. 8:205-216)

Proteasomes are large complexes that carry out the majority of proteolysis
occurring in the cytosol and nucleus of eukaryotic cells, and thereby, perform
crucial roles in cellular regulation and homeostasis (Rechsteiner et al., 2005).
The proteasomal system consists of the so-called 20S ‘core’ proteasome and
several regulatory components that affect its proteolytic activity (Grune, 2000).
The catalytic heart of these complexes, the 20S proteasome (670–700 kDa) is a
barrel-shaped structure, made up of two outer (α) and two inner (β) rings. Three
of the β subunits carry the proteolytic activity of the proteasome, classified as
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caspase-like (β1), trypsin-like (β2), and chymotrypsin-like (β5) activity, which
cleave proteins on the carboxyl side of acidic, basic and hydrophobic amino
acids, respectively (Kapphahn RJ, 2007). Two activators, named 19S (PA700)
and 11S (PA28), are known to bind to the 20S proteasome on both ends, forming
different complexes (Figure 1.3). The 26S proteasome consisting of the 19S and
20S particles degrades proteins in an ubiquitin- and ATP-dependent fashion,
whereas the 11S activator probably allows the 11S/20S complex to degrade only
peptides. Indeed, the binding of the 11S regulator to the 20S proteasome results
in a 3- to 25-fold increase in the degradation of fluorogenic peptides (Grune,
2000). The binding sites for the 11S and the 19S regulator seem to be distinct
and the competition for the core proteasome under in vitro conditions seems to
result in the formation of the 26S proteasome (Hoffmann and Rechsteiner, 1994).
It has been shown that degradation of carbonylated proteins is carried out in
an ATP- and ubiquitin-independent manner by the 20S proteasome, which
selectively recognizes and digests partially unfolded (denatured) oxidized
proteins. For example, oxidized actin is removed by the 20S proteasome during
myocardial ischemia/reperfusion (Divald A, 2005). This notion is further
supported by the finding that the pharmacological inhibition of the 20S
proteasome results in accumulation of carbonylated protein in cell culture (Divald
and Powell, 2006). It is believed that the proteins are presumably targeted to the
20S proteasome via their increased hydrophobicity.

9

Figure 1.3 Different forms of proteasome system. Adapted from Luo et al., Protein
degradation systems in viral myocarditis leading to dilated cardiomyopathy Cardiovasc
Res (2010) 85: 347-356)

The calcium-dependent cysteine protease calpain is located close to the
cytoskeleton and mostly degrade cytoskeletal proteins and membrane proteins.
In cell free systems, calpain has been shown to preferentially degrade oxidized
neurofilament over non-oxidized protein (Troncoso et al., 1995). There is also
evidence suggesting that moderately or heavily oxidized proteins are taken up
via chaperone mediated autophagy by lysosomes, where in some cases they are
incompletely degraded and accumulate resulting in the formation of lipofuscinlike, autofluorescent aggregates (Dunlop et al., 2009). Ubiquitin-dependent
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lysosomal degradation of proteins modified 4-hydroxynonenal (HNE) which is
one type of carbonylation, was also observed in lens epithelial cells (Marques et
al., 2004). Finally, Lon protease preferentially degrades oxidized mitochondrial
protein like aconitase by an ATP-stimulated mechanism.
The efficacy of proteolysis of carbonylated protein likely depends on the
specific protein being carbonylated as well as the level of oxidative damage
(Smerjac and Bizzozero, 2008). While in general proteins become more
susceptible to degradation by cellular proteases upon carbonylation of one or
more residues, heavily oxidized proteins and cross-linked protein aggregates are
not only more resistant to proteolysis but they also inhibit the activity of proteases
that degrade them (Bizzozero, 2009). Thus, accumulation of carbonylated
species may be the result of deficient proteolytic systems and also of decreased
susceptibility of the oxidized proteins to digestion.
Although a number of in vitro experiments have suggested that the four
major proteolytic systems mentioned above are responsible for removing
oxidized proteins, it is not clear that they actually perform this function in vivo or
that they all have a role in removing of carbonylated cytoskeletal proteins in EAE.
For this reason, the ability of these major proteolytic systems to degrade
carbonylated proteins was tested in LPS-stimulated astrocytes. These studies
employed three relatively specific protease inhibitors. As described in Chapter 3,
only the inhibitor epoxomycin leads to a buid-up of carbonylated proteins in
cultured astrocytes, suggesting that carbonylated proteins are mostly removed by
the proteasome. Furthermore, the various proteasomal activities but not calpain
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and lysosomal cathepsin B activities were reduced in chronic EAE. In addition,
the carbonylated cytoskeletal proteins from acute and chronic EAE are equally
sensitive to proteasomal degradation. Overall, this work provides the evidence
that the accumulation of carbonylated cytoskeletal proteins in chronic phase of
EAE likely results from reduced proteasomal activity.
1.4

The peptidolytic activities of 20S proteasome are also impaired in the
cerebrum of MS.
The decreased proteasomal activities, which likely contribute to the

accumulation of carbonylated cytoskeletal proteins in chronic EAE, raised the
question of whether this is also occurring in MS. Therefore, the next set of
studies was designed to determine the activities of the four major proteolytic
systems in the normal-appearing white matter and gray matter of MS patients.
As presented in chapter 4, the three proteolytic activities of 20S proteasome in
MS patients were reduced to ~45% of control values without significant reduction
in proteasome levels. Significant elevations in the activities of both total and
soluble calpain were observed in MS patients and are due to the up-regulation of
calpain expression. Interestingly, the lysosomal activity is increased only in the
MS-gray matter as compared to controls. The mechanisms underlying the
impaired proteasomal activity in MS is currently being investigated in our lab.
1.5

Goal of thesis
My work builds on previous findings in our laboratory that demonstrated an

accumulation of protein carbonyls in the brain of patients with multiple sclerosis
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(MS) and in the spinal cord of rats with acute experimental autoimmune
encephalomyelitis (EAE). The objectives of this thesis were to identify the target
cells and modified proteins of carbonylation in the cerebellum of EAE animals,
and to uncover the mechanisms underlying the accumulation of carbonylated
proteins occurring in the chronic phase of EAE and in MS patients.
The studies described in Chapter 2 are aimed to identify the target cells and
the carbonylated proteins in the cerebellum of animals during the disease course
using a chronic model of EAE. I first demonstrated that carbonyls accumulate in
white matter astrocytes, and to a lesser extent in microglia/macrophages, both in
the acute and chronic phase. Next, I identified β-actin, β-tubulin, GFAP and HSC71 as the major targets of carbonylation throughout disease. Using a pulldown/western blot method I found a significant increase in the proportion of
carbonylated β-actin, β-tubulin and GFAP in the chronic phase but not in the
acute phase. These results suggest that as disease progresses from the
inflammatory to the neurodegenerative phase there may be an inappropriate
removal of oxidized proteins.
Experiments in Chapter 3 were designed to uncover the mechanisms
underlying the accumulation of carbonylated proteins occurring in chronic phase
of EAE. These studies examined the hypothesis that impairment of proteasome
activity may contribute to accumulation of carbonylated cytoskeletal proteins
within cerebellar astrocytes in chronic EAE. To test this hypothesis I first
identified the proteolytic system involved in the removal of carbonylated proteins
employing LPS-stimulated astrocytes and several protease inhibitors. The results
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showed that only the proteasome inhibitor epoxomycin leads to a build-up of
carbonylated proteins within these cells. I then discovered an increase of
chymotrypsin-like proteasome activity (responsible for degradation of oxidized
proteins) in acute EAE followed by a decline in chronic EAE, while neither
lysosomal or calpain activity was impaired in chronic EAE. The accumulation of
poly-ubiquitinated proteins within cerebellar astrocytes observed in the same
animals also confirmed these results. Further, carbonylated cytoskeletal proteins
from acute and chronic EAE were found to be equally sensitive to proteasomal
degradation. All of these results support the notion that diminished proteasomal
activity may be a major contributor to the accumulation of carbonylated
cytoskeletal proteins in the chronic phase of EAE. The mechanism underlying the
decline in proteasome activity will be investigated in future studies.
The diminished proteasomal activity in chronic EAE raised the question of
whether the proteasome activity is also decreased in MS patients. Chapter 4 was
designed to test the activities of four major proteolytic systems in MS patients.
My data showed that the three enzymatic activities of the proteasome in the
normal-appearing gray matter and white matter from MS cerebra are greatly
diminished while the activities of calpain and lysosome in the same samples are
elevated. This similar pattern of proteasomal impairment in chronic EAE and MS
suggests the involvement of this particle in inflammatory demyelinating diseases.
These are the first studies showing proteasomal impairment in chronic EAE and
MS.
Chapter 5 seeks to bring my thesis work together. In this chapter, I discuss
14

some of the findings presented in the previous chapters and present several
important future directions. My preliminary data in chapter 5 shows some
functional consequences of protein carbonylation. I found that the oxidized form
of cytoskeletal proteins including GFAP, β-actin and β-tubulin increase their
solubilities to high concentrations of salt. These preliminary observations provide
evidences of functional disturbance in cytoskeletal proteins under oxidative
stress. A more detailed functionality study should be performed in the future.
Furthermore, this chapter addresses how proteasome may be affected in chronic
EAE/MS, and look at the possibility of preventing proteasomal failure or
activating proteasomal activity for treating these disorders.
Taken together, these publications should lead to future scientific work on
the mechanism underlying the accumulation of oxidized proteins in chronic EAE
and MS. The finding of proteasomal impairment will help us to better understand
the pathophysiology of EAE/MS, and may provide valuable knowledge on which
to base future therapeutic intervention to MS patients.
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2.1 Abstract
Recent work from our laboratory has implicated protein carbonylation in the
pathophysiology of multiple sclerosis (MS) and experimental autoimmune
encephalomyelitis (EAE). The present study was designed to determine the
changes in protein carbonylation during the disease progression, and to identify
the target cells and modified proteins in the cerebellum of EAE animals, prepared
by active immunization of C57/BL6 mice with MOG35-55 peptide. In this model,
protein carbonylation was maximal at the peak of the disease (acute phase) to
decrease thereafter (chronic phase). Double immunofluorescence microscopy of
affected cerebella showed that carbonyls accumulate in white matter astrocytes,
and to a lesser extent in microglia/macrophages, both in the acute and chronic
phase. Surprisingly, T cells, oligodendrocytes and neurons were barely stained.
By 2D-oxyblot and mass spectrometry, β-actin, β-tubulin, GFAP and HSC-71
were identified as the major targets of carbonylation throughout disease. Using a
pull-down/western blot method we found a significant increase in the proportion
of carbonylated β-actin, β-tubulin and GFAP in the chronic phase but not in the
acute phase. These results suggest that as disease progresses from the
inflammatory to the neurodegenerative phase there may be an inappropriate
removal

of

oxidized

cytoskeletal

proteins.

Additionally,

the

extensive

accumulation of carbonylated GFAP in the chronic phase of EAE may be
responsible for the abnormal shape of astrocytes observed at this stage.
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2.2 Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the
human CNS and a major cause of neurological disability among young adults in
North America and Europe (Trapp and Syts, 2009). The pathological changes
that

contribute

to

neurological

disability

in

MS

include

inflammation,

demyelination, oligodendrocyte death and axonal degeneration (Kornek and
Lassmann, 1999). Experimental autoimmune encephalomyelitis (EAE) is a wellestablished animal model for CNS autoimmune disorder, recapitulating a number
of clinical and pathological features of MS (Gold et al., 2000). Several EAE
models have been developed throughout the years that reflect the different
clinical courses of MS. MOG35-55 peptide-induced EAE in the C57BL/6 mouse,
the animal model used in this study, is characterized by the presence of
inflammatory (non-demyelinated) lesions throughout the CNS at the peak of
disease and extensive demyelination with minor inflammation during the chronic
phase (Kuerten et al., 2007). These features make this an ideal model to study
the pathophysiological mechanisms underlying disease progression.
There is substantial amount of data indicating that oxidative stress plays a
major role in the pathogenesis of both MS and EAE. Excessive production of
reactive oxygen species (ROS), primarily by activated microglia/macrophages
and astrocytes, leads to severe oxidative stress, which contributes significantly to
tissue damage (Gilgun-Sherki et al., 2004). The principal outcome of oxidative
stress is the chemical transformation of lipids, proteins, and nucleic acids by
ROS. Of these, proteins are the major target for oxidants as the result of their
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abundance and their high reaction rate constants (Davies, 2005). While the
polypeptide backbone and the side chains of most amino acids are susceptible to
oxidation, the non-enzymatic introduction of aldehyde or ketone functional groups
to specific amino acid residues (i.e. carbonylation) constitutes the most common
oxidative alteration of proteins (Bizzozero, 2009). Protein carbonyls can be
introduced in proteins directly via metal ion-catalyzed oxidation of certain amino
acid residues (Requena et al., 2001) or indirectly by the attachment of bifunctional

reactive

carbonyl

species

(e.g.

4-hydroxynonenal,

acrolein,

malondialdehyde, glyoxal) (Esterbauer et al., 1991). In either case, carbonylation
often leads to loss of protein function and the formation of toxic cross-linked
protein aggregates (Bizzozero, 2009).
Accumulation of protein carbonyls has been implicated in the etiology
and/or progression of several neurodegenerative disorders including Alzheimer’s
disease (Aksenov et al., 2001), Parkinson’s disease (Floor and Wetzel, 1998),
and amyotrophic lateral sclerosis (Ferrante et al., 1997). Our recent discovery
that protein carbonyls accumulate in the brain of MS patients (Bizzozero et al.,
2005; Hilgart and Bizzozero, 2008) and in the spinal cord of rats with acute EAE
(Smerjac and Bizzozero, 2008), suggests that this type of chemical modification
may also play a critical pathophysiological role in inflammatory demyelinating
diseases. The present study was designed to assess the levels of protein
carbonylation and to identify the target cells and the modified proteins in the
cerebellum of EAE mice during the course of the disease. The results show that
most of the carbonyls accumulate in white matter astrocytes, and to a lesser
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extent in microglia/macrophages, present at the site of inflammatory lesions both
at the peak of disease and during the chronic phase. Surprisingly, T cells,
oligodendrocytes and neurons were barely stained. At all disease stages, the
major carbonylated proteins were identified as β-actin, β-tubulin, GFAP and heat
shock cognate-71 (HSC-71). While both oxidative stress and total protein
carbonylation decrease later in the disease, we observed that the proportion of
the carbonylated forms of the cytoskeletal proteins was notably higher in the
chronic animals. This suggests impairment in the removal of oxidized proteins as
disease progresses. A preliminary account of this work has been presented in
abstract form (Zheng and Bizzozero, 2009).
2.3 Materials and Methods
2.3.1 Induction of Experimental Autoimmune Encephalomyelitis (EAE)
Housing and handling of the animals as well as the euthanasia procedure
were in strict accordance with the NIH Guide for the Care and Use of Laboratory
Animals, and were approved by the Institutional Animal Care and Use Committee.
Eight-week-old female C57BL/6 mice were purchased from Harlan Bioproducts
(Indianapolis, IN) and housed in the UNM-animal resource facility. To induce
EAE, animals received a subcutaneous injection into the lower back area of
200µl of MOG35-55 peptide (200µg) (AnaSpec, San Jose, CA) in saline mixed
with complete Freund's adjuvant (CFA) supplemented with 4 mg/ml of heat killed
Mycobacterium tuberculosis H37Ra (Chondrex Inc; Redmond, WA). Control
animals were given CFA without MOG peptide. Two-hours and 48h after EAE
induction, all animals received an i.p. injection of 0.3 µg of pertussis toxin (List
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Biological Laboratories; Campbell, CA) in 100 µl of saline. Seven days after
disease induction mice received a second immunization with the MOG peptide in
CFA. Animals were weighed and examined daily for the presence of neurological
signs. At prescribed days post-immunization (DPI), EAE mice and CFA-injected
controls were euthanized by decapitation. The cerebellum was removed and
either fixed with methacarn (methanol : chloroform : acetic acid, 60 : 30 : 10 by
vol) or homogenized in PEN buffer (20 mM sodium phosphate, pH 7.5, 1 mM
EDTA, and 0.1 mM neocuproine) containing 2 mM 4,5 dihydroxy-1,3 benzene
disulfonic acid and 1 mM dithiothreitol (DTT). Protein homogenates were stored
at -20°C until use. Protein concentration was asses sed with the Bio-Rad DC™
protein assay (Bio-Rad Laboratories; Hercules, CA) using bovine serum albumin
as standard.

2.3.2 Biochemical determination of oxidative markers
The amount of non-protein thiols, of which > 90% is reduced glutathione
(GSH) was determined with 5,5'-dithiobis-(2-nitrobenzoic acid) (Bizzozero et al.,
2006). Lipid peroxidation was assessed by measuring the amount of
thiobarbituric acid reactive substances (TBARS) in the tissue homogenates
(Ohkawa et al., 1979). The relative amount of protein carbonyls was measured
with the OxyBlot™ protein oxidation detection kit (Intergen Co., Purchase, NY) as
described elsewhere (Bizzozero et al., 2006).
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2.3.3 Two-dimensional oxyblots of cerebellar proteins
Cerebellar proteins (5 µg) were first incubated with 2,4-dinitrophenylhydrazine (DNPH) to convert the carbonyl groups into 2,4-dinitrophenyl (DNP)
hydrazone derivatives, and were then analyzed by 2D-gel electrophoresis
(Smerjac and Bizzozero, 2008). After electrophoresis, proteins were blotted to
polyvinylidene difluoride (PVDF) membranes. DNP-containing proteins were
detected using rabbit anti-DNP antiserum (1:5000) and goat anti-rabbit IgG
conjugated to horseradish peroxidase (1:2000). Blots were developed by
enhanced chemiluminescence (ECL) using the Western Lightning ECL™ kit from
Perkin-Elmer (Boston, MA). Blots were stripped and re-probed with antibodies
against specific cytoskeletal proteins including β-tubulin (1:1000, mouse
monoclonal; Sigma, St Louis, MO), GFAP (1:1000, mouse monoclonal; Sigma)
and β-actin (1:1000, mouse monoclonal; GeneTex, Irvine, CA). As before, blots
were developed by ECL.

2.3.4 Identification of major carbonylated proteins by mass-spectrometry
Spot matching between the 2D-oxyblots and the coomassie blue stained
2D-gels was performed using the Discovery Series PDQuest 2-D Analysis
Software Version 7.0.1 (Bio-Rad). Protein spots were excised from the gel and
subjected to in situ digestion with trypsin (Bizzozero et al., 2002). Before massspectrometry, peptides were cleaned-up and concentrated using C-18 Zip-tips
(Millipore Corp., Billerica, MA) and mixed with -cyano-4-hydroxycinnamic acid.
Mass spectra were acquired on a Biosystems 4700 Proteomics Analyzer
(TOF/TOF) (Applied Biosystems/MDX Sciex, Foster City, CA) in positive ion
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reflection mode and using a S/N threshold of 30. Monoisotopic peak lists were
generated employing a GPS Exporer™ software (v3.5, Applied Biosystems) and
were submitted to the MASCOT search tool for protein identities. For all searches,
precursor ion mass tolerance was 100 ppm. Protein identification was considered
significant with a Mascot score corresponding to p<0.05.

2.3.5 Quantification of carbonylation levels in specific proteins
The extent of protein carbonylation was determined using a pulldown/western blot method (Bizzozero et al., 2006). Briefly, protein carbonyls
were biotinylated by reaction with biotin hydrazide in the presence of
cyanoborohydride. A small aliquot of these protein homogenates was saved for
western blotting and the rest was processed to isolate the biotinylated proteins
using streptavidin-agarose. Proteins were eluted from the beads with SDSsample buffer and analyzed by western blotting on 10% polyacrylamide gels.
Blots were probed with antibodies against individual protein species and
developed by ECL as described above.

Films were scanned in a Hewlett

Packard Scanjet 4890 and the images were quantified using the NIH Image 1.63
imaging analysis program. Band intensities from the total and streptavidin-eluted
fractions were used to calculate the percent of protein modified by carbonylation.

2.3.6 Immunohistochemical detection of protein carbonyls
Tissue specimens were fixed overnight in methacarn and then mounted in
paraffin. Tissue was sectioned in the sagital plane (6-µm thick) and mounted on
Vectabond™-treated slides (Vector Laboratories, Burlingame, CA). Sections
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were deparafinized with xylenes and a graded alcohol series, and then rinsed
with phosphate-buffered saline (PBS) solution for 10 min. Lesions were detected
by staining with hematoxylin and eosin (H&E). Adjacent sections were incubated
for 30 min with 1 mg/ml DNPH prepared in 2 N HCl to convert carbonyl groups
into DNP-hydrazones. Sections were rinsed three times with PBS, blocked with
10% (v/v) normal goat serum and incubated overnight with rabbit anti-DNP
antibody (1:1000) (Sigma). After removing the primary antibody with PBS
containing 0.1% Triton X-100, sections were incubated for 3 h with Alexa Fluor®
647 goat anti-rabbit antibody (1:100, Molecular Probes, Eugene, OR). Sections
were rinsed twice with PBS containing 0.1% Triton X-100, once with PBS, and
then mounted in a buffered glycerol solution containing p-phenylenediamine as
anti-fade reagent. Images were captured with a Zeiss 200m microscope (Carl
Zeiss MicroImaging Inc., Thornwood, NY) equipped with a Hamamatsu C474295 digital camera (Hamamatsu Corp., Bridgewater, NJ).
For double immunofluorescence, DNPH-treated sections were incubated
with the mixture of two primary antibodies overnight at 4˚C, followed by
incubation with the corresponding fluorescent secondary antibodies (Alexa
Fluor® 488 and Alexa Fluor® 647, 1:100, Molecular Probes). After washing, the
sections were cover slipped with anti-fade fluorescent mounting medium. The
various cell types were detected by using antibodies against GFAP (1:500,
mouse monoclonal; Sigma), Iba1 (1:250, mouse monoclonal, Santa Cruz
Biotechnology, Santa Cruz, CA), CD3 (1:100, mouse monoclonal, Santa Cruz),
adenomatous polyposis coli protein C-terminal (1:125, mouse monoclonal,
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Chemicon, Temecula, CA) and NeuN (1:250, mouse monoclonal, Chemicon). To
quantify the percentage of each cell type that shows positive carbonyl deposits,
slide-mounted sections were scanned at a 60X magnification and were
digitalized with a MagnaFire Camera (Optronics, Galeta, CA). Images were
imported into Image J software to obtain merged pictures. Three fields (100µm x
75µm) per slide and three slides per animal were chosen for quantification.

2.3.7 Statistical Analysis
Results were analyzed for statistical significance with ANOVA utilizing
GraphPad Prism® program (GraphPad Software Inc., San Diego, CA).

2.4 Results
2.4.1 Characteristics of EAE mice
EAE in female C57BL/6 mice was induced by active immunization with
MOG35-55 peptide as described under Materials and Methods. Symptoms were
graded according to the following scale: 0, no symptoms; 1, tail weakness; 1.5,
clumsy gait; 2, hind limb paresis; 2.5, partial hind limb dragging; 3, hind limb
paralysis; 3.5, hind limb paralysis with fore limb paresis; 4, complete paralysis;
and 5, moribund. In this EAE model, neurological symptoms begin at 14 DPI (7
days after the boost with MOG peptide) reaching a peak at 30 DPI, and most
animals remain ill (score 3.0-3.5) throughout the entire experimental period (60
DPI) (Figure 2.1A). Acute disease was defined as having maximal neurological
symptoms of EAE without any improvement for at least three consecutive days.
At this stage the cerebellar pathology is characterized perivenular infiltration of
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inflammatory cells mostly within the white matter (Figure 2.1C). Chronic EAE was
defined arbitrarily as animals that remain in the stationary phase of the disease
for 30 days (60 DPI). At this stage there is reduced perivascular and
parenchymal inflammation, and lessened transmigration of inflammatory cells
into the cerebellum (Figure 2.1D). CFA-injected animals, which were sacrificed at
30DPI (control young) and 60DPI (control old), did not exhibit any neurological
sign or cerebellar pathology (Figure 2.1B). Western blot analysis of cerebellar
proteins using antibodies against several myelin proteins, neurofilament proteins
and GFAP revealed that cerebella from acute EAE animals have increased
gliosis without apparent demyelination or axonal injury. In contrast, chronic EAE
cerebellar tissue has reduced gliosis and augmented demyelination and axonal
damage (data not shown). These results are in agreement with the current notion
that acute EAE is mainly an inflammatory disorder while chronic EAE is mostly a
demyelinating/neurodegenerative disorder (Kuerten et al., 2007).

2.4.2 Increase oxidative stress in acute and chronic EAE
As shown in Figure 2.2A, GSH levels in EAE cerebella was 73% and 85%
of control values at the peak of disease and in the chronic phase, respectively.
This indicates that the CNS of the affected animals is indeed subjected to
considerable oxidative stress. Interestingly, the amount of TBARS, a marker of
lipid peroxidation, in EAE animals was similar to that in controls both at peak of
the disease and in the chronic phase (Figure 2.2B). Quantitative analysis of the
oxyblots revealed a significant enhancement in protein carbonyl levels in the
acute phase with little or no changes in the chronic phase of EAE (Figure 2.2C).
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2.4.3 Protein carbonyls accumulate within astrocytes present at the lesion’s
sites
Immunohistochemical localization of carbonyls groups was carried out
after derivatizing these moieties with DNPH (Figure 2.3). Validation of this
technique was performed by omitting the DNPH-treatment, the anti-DNP
antibody or the secondary anti-rabbit IgG antibody (not shown). We also carried
out a positive control in which carbonyls were generated by incubating cerebellar
sections with FeSO4/H2O2 (Figure 2.3E) and a specificity control in which
endogenous carbonyls were removed by incubation with NaBH4 (Figure 2.3F).
Using this technique we found that carbonyl staining in the cerebellum of both
acute (Figure 2.3B) and chronic EAE mice (Figure 2.3D) is highly intense in the
white matter, where the majority of inflammatory lesions are present. As
expected from the biochemical data shown in Figure 2.3C, there is higher density
of carbonyl staining in the acute phase than in chronic phase. In addition, the
morphology of most carbonyl-positive cells appears to be that of astrocytes. This
was confirmed by immunostaining carbonyls and GFAP simultaneously (Figure
2.4). It is worth noting that, in the acute tissue, astrocytes have normal
morphology and show colocalization with GFAP and carbonyl in their distal
processes, while in the chronic tissue, astrocytes exhibit an abnormal
morphology. Indeed, some astrocyte processes are completely retracted.
Double immunofluorescence with antibodies against DNP and different
cell-specific markers was used to identify other major cell targets of carbonylation.
As depicted in Figure 2.5, the majority of astrocytes (~90%) present at the site of
inflammatory lesions in chronic EAE showed positive carbonyls staining, and
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similar results were found in acute EAE (data not shown). A significant proportion
of microglial cells/macrophages (40%) also showed carbonyl staining, while
<10% of T cells (CD3+), <5% of oligodendrocytes (APC+) and <10% of neurons
(NeuN+) were stained with the anti-DNP antibody.

2.4.4 Identification of the major protein targets of carbonylation in EAE
Two-dimensional-oxyblot of cerebellar proteins from acute EAE mice shows
the presence of 4 major carbonylated polypeptides and several minor species
that become visible at much longer exposure times (Figure 2.6). These major
oxidized species were also present in oxyblots of cerebellar proteins from chronic
EAE animals (not shown). This particular 2D-pattern of carbonyls was somewhat
reminiscent to that of found in the spinal cord of EAE rats, where cytoskeletal
proteins are the major targets of carbonylation (Smerjac and Bizzozero, 2008).
Thus, identification of carbonyl-containing proteins was initially carried out by
spot matching DNP-labeled proteins on a 2D-oxyblot with those of specific
cytoskeletal elements. Using this approach we identified three of the major
carbonylated spots as β-actin, β-tubulin and GFAP. The other major spot in the
2D-oxyblot did not correspond to any of the other cytoskeletal species and was
identified by mass-spectrometry as HSC-71 (P63017; mascot score= 208).
Experiments were also conducted to ascertain the chemical nature of the
carbonyls. Western blot analysis using antibodies against acrolein, 4hydroxynonenal and malondialdehyde failed to detect the presence of any
modified protein in either control or EAE mice (data not shown), suggesting that
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reactive carbonyl species-protein adducts are not formed in this disease. Thus,
most carbonyl groups present in the oxidized proteins are likely to be aminoadipic semialdehyde and glutamic semialdehyde, which are formed by
direct, metal-ion catalyzed, oxidative deamination of the amino acid side chain of
proline, arginine and lysine (Requena et al., 2001).

2.4.5 Accumulation of carbonylated cytoskeletal proteins in chronic EAE.
Quantification of the extent of carbonylation of individual proteins was
performed using a pull-down/western blot procedure. To this end, protein
carbonyl moieties from control and EAE cerebellar homogenates were first
converted into biotinylated residues by reaction with biotin-hydrazide. Biotincontaining proteins were then isolated with streptavidin-agarose and analyzed by
western blotting employing antibodies against the β-tubulin, β-actin and GFAP.
HSC-71 was not studied due to the lack of an appropriate antibody. A number of
preliminary studies were carried out to ascertain (1) the concentration of biotin
hydrazide and time necessary for complete blockage of carbonyl groups, (2) the
amount of streptavidin-agarose necessary for complete binding of biotinylated
proteins, and (3) the composition and number of rinses that ensure the proper
removal of non-biotinylated proteins from the agarose beads before elution. Also,
no material was recovered from the streptavidin agarose when either the biotin
hydrazide was omitted from the derivatization step or when the carbonyl groups
were eliminated by pre-incubation with sodium borohydride, indicating that the
procedure for isolating carbonylated proteins is indeed specific. Figure 2.7 shows
the percentage of individual proteins that is modified by carbonylation in control
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and EAE animals, which was calculated from the amount of each protein in the
bound and total fractions. Surprisingly, the proportion of oxidized β-actin, βtubulin and GFAP did not increase in acute EAE as compared to young control
mice. The reason for the apparent discrepancy between these findings and those
obtained with the 2D-oxyblots (Figure 2.6) is due to the fact that there is more βactin and GFAP in the cerebellum of acute EAE than in control animals. In
contrast, there is a five-fold increase in the proportion of carbonylated GFAP and
a two-fold increase in the proportion of carbonylated β-actin and β-tubulin in
chronic EAE mice relative to its control. These results suggest that as disease
progresses from the inflammatory to the neurodegenerative phase there may be
an inappropriate removal of the carbonylated forms of these cytoskeletal proteins.

2.5 Discussion
This is the first study on the accumulation of oxidized CNS proteins during
the course of chronic EAE. We focused our research on the cerebellum since this
CNS region is commonly affected in MS (Ramasamy et al., 2009) and in MOG
peptide-induced EAE (MacKenzie-Graham et al., 2009). Furthermore, the
pathophysiological changes in the cerebellum remain largely unexplored when
compared to the spinal cord, the CNS area most studied in EAE. Using classical
immunocytochemical techniques, we found that the majority of the carbonyl
groups are localized within astrocytes located in the vicinity of inflammatory
lesions both at the peak of the disease and during the chronic phase. A number
of microglial cells/macrophages were also found to contain detectable levels of
carbonyls in EAE, while T cells, oligodendrocytes and neurons were mostly
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unstained. This result is not totally unexpected since upon inflammatory
activation both microglia and astrocytes produce large amounts of ROS (Keller et
al., 1999) that could generate significant amounts of carbonyls within these cells.
Furthermore, microglial cells contain higher levels of glutathione and antioxidant
enzymes

(superoxide

dismutase,

catalase,

glutathione

peroxidase

and

glutathione reductase) than astrocytes (Dringen, 2005), which may protect the
former from a more severe oxidative damage. Nonetheless, it was somewhat
surprising to find that neurons and oligodendrocytes do not have extensive
carbonyl staining, particularly when these two cell types are considered by many
investigators to be highly susceptible to oxidative stress (Halliwell, 2006;
Benarroch, 2009). Interestingly, the notion that astrocytes are less sensitive to
oxidative damage than other CNS cells has been recently challenged. It has
been found that cerebellar astrocytes in the unperturbed mouse contain
significantly

lower

levels

of

reduced

glutathione

than

neurons

and

oligodendrocytes (Miller et al., 2009). Another possibility to explain the selective
oxidation of cells in our model is that the ROS generated by activated
microglia/macrophages and astrocytes are short lived and do not reach other cell
targets. Finally, oligodendrocytes and neurons may have a more efficient
proteolytic machinery to remove oxidized proteins thus reducing the build up of
carbonylated proteins in these cells. This may be also the case for T cells, whose
proteasomal activity is enhanced during inflammation (Mattingly et al., 2007).
Another significant finding in this study was the identification of β-actin, βtubulin, GFAP and HSC-71 as major targets of protein carbonylation in the

31

cerebellum of both acute and chronic EAE. It should be noted that the detection
and identification of oxidized species using a 2D-oxyblot is biased toward
abundant cell proteins and that longer exposure times reveals the presence of
other modified species. However, many proteins are as abundant as β-actin, βtubulin and GFAP and yet they have minimal carbonylation (e.g. spectrin) or their
oxidation does not change in EAE (e.g. vimentin), which suggests specificity.
Indeed, metal ion-catalyzed oxidation of Escherichia coli proteins seems to be
highly selective with most carbonylation sites present in RKPT-enriched regions
that are exposed to the solvent (Maisonneuve et al., 2009). It has been known for
some time that in neurodegenerative disorders cytoskeletal proteins are
particularly susceptible to carbonylation (Aksenov et al., 2001; Muntané et al.,
2006). Furthermore, previous work from our lab has also identified β-actin, βtubulin and GFAP as significant targets of carbonylation in the brain of MS
patients (Hilgart and Bizzozero, 2008) and in the spinal cord of rats with acute
EAE (Smerjac and Bizzozero, 2008).
Carbonylation of cytoskeletal proteins has been reported to cause loss of
function. For instance, actin filaments and microtubules both destabilize and
disassemble upon oxidation of their protein components (Dalle-Donne et al.,
2001; Neely et al., 2005). Oxidative damage of GFAP has been described in
Alzheimer's disease (Korolainen et al., 2005; Pamplona et al., 2005),
aceruloplasminaemia (Kaneko et al., 2002), Pick's disease (Muntané et al., 2006)
and MS (Hilgart and Bizzozero, 2008). Whether the accumulation of oxidized
GFAP is associated with loss of function, as demonstrated for the other
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cytoskeletal proteins, is not known. Because GFAP is a main intermediate
filament of cytoskeleton that modulates astrocyte stability and shape, it is
possible that the accumulation of oxidized GFAP may have an effect on astrocyte
morphology. Interestingly, carbonyl-positive astrocytes in chronic EAE, where the
proportion of oxidized GFAP is relatively high, have very short processes and
there is redistribution of this protein from the processes to the soma. In contrast,
normal morphology of activated astrocytes with long processes was observed at
the peak of the disease where, despite the large excess of GFAP, the proportion
of oxidized protein is just above control values. Carbonylation may also affect
other GFAP properties such as the anchoring of the glutamate transporter
GLAST to the plasma membrane of astrocytes, which seems to play an important
role in protecting the brain against glutamate-mediated excitotoxicity (Sullivan et
al., 2007). Significant carbonylation of HSC-71 was detected in both EAE and
control cerebella, suggesting that this chaperone is highly susceptible to
oxidation. HSC-71 is a constitutively expressed and multifunctional chaperone
protein present in both neurons and activated astrocytes (Kanninen et al., 2004).
Based on its involvement in the structural maintenance of the proteasome and
conformational recognition of misfolded proteins by proteases, HSC-71
expression has been proposed as a defensive mechanism of response to
unfavorable conditions. While our study is the first to describe carbonylation of
HSC-71, other chaperones are known to exhibit an age-associated increase in
carbonylation including BiP/Grp78, protein disulfide isomerase, and calreticulin
(Rabek et al., 2003).
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In present study, the total amount of carbonylated protein at the peak of
disease is significantly increased compared to that of control animals, while little
change is found during the chronic phase of EAE. This is likely due to the lower
number/activity of inflammatory lesions, the site where protein carbonyls build-up,
in the chronic phase of EAE. Indeed, immunohistochemical studies revealed that
carbonyls accumulate in the diseased white matter in both phases of EAE (Fig.
3). Moreover, the percentage of oxidized GFAP, β-tubulin and β-actin in the
chronic phase are considerably higher than those in the acute phase. While the
proportion of carbonylated cytoskeletal proteins measured in the cerebellum
homogenate of chronic animals seems low (~2% for GFAP), one has to consider
that these oxidized molecules may be distributed heterogeneously. Thus, the
proportion of modified cytoskeletal proteins in cells near inflammatory foci may
be much higher than that determined in the pull-down assays from the entire
tissue. The amount carbonylated protein is determined by the rate of generation
and degradation of carbonyls. Proteolysis is considered the only physiological
mechanism for elimination of carbonylated proteins since there is no evidence for
enzymatic reduction of protein-bound carbonyl groups to alcohols (Bizzozero,
2009). Therefore, since protein carbonyls cannot be repaired and since there is
less oxidative stress in chronic than in acute EAE, it is fair to conclude that the
accumulation of carbonylated cytoskeletal proteins in the cerebellum of chronic
EAE mice may be due to impaired degradation. This, in turn, could be caused by
reduced activity of the degradation system and/or by decreased susceptibility of
the oxidized proteins to proteolysis. Degradation of carbonylated proteins is
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thought to be carried out in an ATP- and ubiquitin-independent manner by the
20S proteasome, which selectively recognizes and digests partially unfolded
oxidized proteins (Rivett, 1985; Grune et al., 1995). Interestingly, preliminary
studies in our laboratory discovered a significant decrease in proteasome activity
in chronic EAE, which might explain the accumulation of oxidized proteins as
disease progresses (Zheng and Bizzozero, 2010). At this time, however, we
cannot exclude that oxidized cytoskeletal proteins are also less susceptible to
digestion by the proteasome and other cellular proteases as previously proposed
(Friguet et al., 1994). Studies in our laboratory are underway to examine this
possibility.
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Figure 2.1 Clinical course and cerebellar pathology of EAE in C57BL/6 female
mice.EAE was induced by active immunization with MOG35-55 peptide as
described under Materials and Methods. Animals were monitored daily for signs
of clinical disease and scored as indicated in the text. Clinical scores represent
the mean of 6 control and 10 EAE mice (panel A). Panels B-D depict
representative H&E-stained cerebellar sections from control, acute EAE and
chronic EAE mice, respectively. GL, granule cells layer; ML, molecular layer; WM,
white matter. In panel C, arrows point to perivenular white matter lesions with
abundant lymphocyte infiltration in the acute EAE. In panel D, arrows point to
perivenular white matter lesions in chronic EAE that show reduced inflammatory
activity. Bar= 300µm.
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Figure 2.2 Levels of oxidative stress markers in the cerebellum of acute and
chronic EAE mice. Aliquots of cerebellar homogenates from control and EAE
mice were used to determine the levels of reduced glutathione (panel A), TBARS
(panel B) and protein carbonyls (panel C) as described in Materials and Methods.
Values represent the mean ± SEM of 5 animals in each experimental group.
Asterisks denote values that are statistically different (p<0.05) from their
respective controls.
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Figure 2.3 High levels of carbonyls in cerebellar white matter of acute and
chronic EAE mice. Cerebellar sections (6µm-thick) from control, acute EAE and
chronic EAE mice were incubated with DNPH to convert carbonyls into DNPderivatives, which were detected by sequential incubation with rabbit anti-DNP
and Alexa Fluor® 647 (red) goat anti-rabbit antibodies as described under
Materials and Methods (panels A-D). Panels E and F show cerebellar sections
from control animals that were pretreated with Fe/H2O2 to generate carbonyls
(positive control) and with NaBH4 to remove endogenous carbonyls (negative
control), respectively. Bar= 300µm. Other abbreviations are as in Fig 1.
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Figure 2.4 Colocalization of carbonyls and GFAP in the cerebellum of acute and
chronic EAE mice. Double immunofluorescence analysis was performed as
described in Methods and Materials. Green channel is for GFAP-positive
astrocytes while red channel is for carbonyls. Immunofluorescent images show
that the majority of white matter astrocytes in the cerebellum of acute and chronic
EAE mice contain significant amounts of carbonyls. In acute EAE, cerebellar
astrocytes have normal morphology and show colocalization of GFAP and
carbonyl staining in their distal processes. In chronic EAE, cerebellar astrocytes
exhibit abnormal morphology including the retraction of some processes. Bar=
50µm.
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Figure 2.5 Carbonyl staining in the cerebellum of chronic EAE mice colocalizes
mostly with astrocytes and some microglial cells. Double immunofluorescence
analysis was performed as described in Methods and Materials. Green channel
is for the various cell markers while red channel is for carbonyls.
Immunofluorescent images show that the majority of cerebellar astrocytes
(GFAP+) (panel A) and a significant proportion of microglia/macrophages (Ib1a+)
in chronic EAE mice (panel B) are positive for carbonyls. In contrast, only a few
CD3+-Tcells (panel C), NeuN-expressing neurons (panel D) and APC+oligodendrocytes (panel E) show positive carbonyl staining. Bar= 50µm.
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Figure 2.6 β-Actin, β-tubulin, GFAP and HSC-71 are the major carbonylated
proteins in EAE cerebellum. Cerebellar proteins from control and EAE mice were
derivatized with 2,4-dinitrophenylhydrazine. Proteins were separated by 2-D-gel
electrophoresis

and

blotted

to

PVDF

membranes.

Membranes

were

immunostained with anti-DNP, then stripped and re-probed with antibodies
against the major cytoskeletal proteins. β-Actin, β-tubulin and GFAP on the
oxyblots were identified by spot matching. HSC-71 was identified by mass
spectrometry as described in Materials and Methods. Only the pH 3-6 region of
the oxyblots is shown since the pH 6-10 region was devoid of visible carbonylpositive spots.
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Figure 2.7 GFAP, β-actin and β-tubulin are more carbonylated in chronic than in
acute EAE. Carbonylated proteins were converted into biotinylated proteins and
were isolated using streptavidin-agarose as described under Materials and
Methods. Aliquots of the starting material (total) and the streptavidin-purified
fraction (bound) were separated on SDS-gels and transferred to PVDF
membrane. Blots were probed with antibodies against various proteins and were
developed by ECL (panel A). Densitometric scans were obtained to calculate the
proportion of each protein that is carbonylated (panel B). Values represent the
mean ± SEM of five animals. * p<0.05.
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3.1 Abstract
We have recently shown that several carbonylated proteins, including GFAP,
β-actin and β-tubulin, accumulate within cerebellar astrocytes during the chronic
phase of MOG35-55 peptide-induced EAE in C57BL/6 mice. Since protein
carbonyls cannot be repaired and there is less oxidative stress in chronic than in
acute EAE, we hypothesized that the accumulation of carbonylated proteins in
the former animals may be due to a defect in the degradation of the modified
proteins. Alternatively, oxidized proteins in chronic EAE mice may be more
resistant to proteolysis. Using LPS-stimulated astrocytes and several protease
inhibitors we identified the 20S proteasome as the proteolytic system responsible
for the elimination of most oxidized proteins. We also discovered that the
chymotrysin-like and caspase-like activities of the 20S proteasome are impaired
in chronic EAE, while the amount of proteasome was unchanged. Proteasome
failure in these animals was confirmed by the build-up of ubiquitinated proteins,
mostly within astrocytes. In a cell-free system, carbonylated proteins from EAE
mice with acute and chronic disease seem to be equally sensitive to proteasomal
degradation. Altogether, the results support the notion that diminished activity of
the 20S proteasome is a major contributor to the accumulation of carbonylated
proteins in astrocytes of chronic EAE mice.

3.2 Introduction
Carbonylation refers to the non-enzymatic addition of aldehyde or ketone
groups to specific amino acid residues and constitutes the major and most
common oxidative alteration of proteins (Dalle-Donne et al., 2003; Nystrom,
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2005). Like in several CNS disorders, including Alzheimer’s disease (Aksenov et
al., 2001), Parkinson’s disease (Floor & Wetzel, 1998) and amyotrophic lateral
sclerosis (Ferrante et al., 1997), multiple sclerosis (MS) (Bizzozero et al., 2005;
Hilgart & Bizzozero, 2008) and its animal model experimental autoimmune
encephalomyelitis (EAE) are also characterized by accumulation of carbonylated
(oxidized) proteins (Smerjac & Bizzozero, 2008; Zheng & Bizzozero, 2010a).
Carbonylation leads almost always to loss of protein function and is believed to
partake in the etiology of these neurological diseases (for a review, see
Bizzozero, 2009). In MOG35-55 peptide-induced EAE, the amount of the most
abundant carbonylated proteins (e.g., β-actin, β-tubulin and GFAP) in cerebellar
astrocytes was found to augment as disease advances from the inflammatory
(acute) phase to the neurodegenerative (chronic) phase (Zheng & Bizzozero,
2010a), suggesting that this deleterious protein modification may play a role in
disease progression as well.
It is clear that the amount of carbonylated protein is determined by the rates
of generation and degradation of carbonyls. Proteolysis is currently considered
the only physiological mechanism for elimination of carbonylated proteins, as
there is no evidence for enzymatic reduction of protein-bound carbonyl groups to
alcohols (Bizzozero, 2009). This and the fact that there is less oxidative stress in
chronic than in acute EAE (Zheng & Bizzozero, 2010a) suggest that the
accumulation of carbonylated cytoskeletal proteins in the cerebellum of chronic
EAE mice may be due to impaired degradation. This phenomenon, in turn, could
be the result of reduced activity of the degradation system and/or decreased
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susceptibility of the oxidized proteins to proteolysis. In mammalian cells, the
removal of carbonylated proteins is mostly carried out by the 20S proteasome in
an ATP- and ubiquitin-independent manner (Shringarpure et al., 2003; Divald &
Powell, 2006). This multi-enzymatic proteolytic particle selectively recognizes
and digests partially unfolded (denatured) oxidized proteins through its
chymotrypsin-like activity (Ferrington et al., 2005). However, the calciumdependent cysteine protease calpain and the lysosomal cathepsins have been
also implicated in the proteolytic removal of damaged proteins. For instance,
oxidized neurofilaments seem to be preferentially digested by calpain in vitro
(Troncoso et al., 1995) while heavily oxidized proteins are take-up by lysosomes
for partial proteolysis (Dunlop et al., 2009).
In this study, we initially assessed the role of these three major degradation
systems in the accumulation of carbonylated proteins in LPS-stimulated
astrocytes by using well-characterized protease inhibitors. The results clearly
show that only the proteasome inhibitor epoxomicin leads to a build-up of
carbonylated proteins, while inhibition of lysosomal proteases and calpain do not
alter protein carbonylation levels. More important, we discovered that the
chymotrypsin-like activity of the 20S proteasome is impaired in the cerebellum of
mice with chronic, but not acute, EAE. This observation was also consistent with
the accumulation of poly-ubiquitinated proteins within cerebellar astrocytes
observed in the animals with the chronic disease. Furthermore, experiments in a
cell-free system showed that carbonylated cytoskeletal proteins from acute and
chronic EAE are equally sensitive to proteasomal degradation. Overall, this work
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provides clear evidence that supports the notion that the accumulation of
carbonylated proteins in chronic EAE is likely the result of reduced proteasomal
activity. To the best of our knowledge, this the first report implicating proteasome
dysfunction in the pathophysiology of EAE. A preliminary account of this work
has been presented in abstract form (Zheng & Bizzozero, 2010b).

3.3 Materials and Methods
3.3.1 Astrocyte culture
Rat C6 glioblastoma cells (CCL-107) were obtained from American Type
Culture Collection (Manassas, VA) and were established as a monolayer culture
in Dulbecco's modified Eagle's/F-12 medium supplemented with 15% horse
serum, 2.5% fetal bovine serum and an antibiotic/antimycotic mixture (Invitrogen
Corp., Carlsbad, CA). Cells were maintained in a humidified incubator at 37°C in
an atmosphere of 95% air / 5% CO2. To be differentiated into astrocytes, C6
cells were serum-starved for 1h and then incubated with 1mM N6-2’-O-dibutyryl
cyclic-AMP (Bt2AMP; Sigma, St Louis, MO) and 0.25 mM theophylline (Sigma)
for up to 72h. At this point, astrocytes were activated with 1µg/ml
lipopolysaccharide (LPS; Sigma) for 24 hours. Nitrite concentration in the cell
supernatants

was

determined

spectrofluorometrically

using

2,3–

diaminonaphthalene (Misko et al., 1993) and non-protein thiol (mostly GSH)
levels in the cell homogenates were determined with 5,5'-dithiobis-(2-nitrobenzoic
acid) (Bizzozero et al., 2006). To identify the proteolytic system responsible for
degradation of carbonylated cytoskeletal proteins, LPS-treated and untreated
astrocytes were incubated in the absence or presence of the proteasome
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inhibitor epoxomicin (2 µM; Boston Biochemical, Cambridge, MA), the lysosomal
inhibitor NH4Cl (2mM, Sigma) or the calpain inhibitor calpeptin (20µM, Sigma).
After 24h, cells were either fixed with methacarn (methanol : chloroform : acetic
acid, 60 : 30 : 10 by vol) or lysed in PEN buffer (20 mM sodium phosphate, pH
7.5, 1 mM EDTA, and 0.1 mM neocuproine) containing 2 mM 4,5 dihydroxy-1,3benzene disulfonic acid and 1 mM dithiothreitol (DTT). Protein homogenates
were stored at -20°C until use. Protein concentrati on was assessed with the BioRad DC™ protein assay (Bio-Rad Laboratories; Hercules, CA) using bovine
serum albumin as standard.

3.3.2 Induction of Experimental Autoimmune Encephalomyelitis (EAE)
Housing and handling of the animals as well as the euthanasia procedure
were in strict accordance with the NIH Guide for the Care and Use of Laboratory
Animals, and were approved by the Institutional Animal Care and Use Committee.
Eight-week-old female C57BL/6 mice were purchased from Harlan Bioproducts
(Indianapolis, IN) and housed in the UNM-animal resource facility. EAE was
induced by active immunization with MOG35-55 peptide (AnaSpec, San Jose,
CA) as described in our previous study (Zheng & Bizzozero, 2010a). Animals
were weighed and examined daily for the presence of neurological signs. At
prescribed days post-immunization (DPI), EAE mice and CFA-injected controls
were euthanized by decapitation. The cerebellum was removed and either fixed
with methacarn (methanol : chloroform : acetic acid, 60 : 30 : 10 by vol) or
homogenized in PEN buffer with antioxidants. Protein homogenates were stored
and processed as described above.
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3.3.3 Protease activity assays
The various proteolytic activities of the proteasome were determined in
cerebellar homogenates from control and EAE mice using fluorescence assays
(Rodgers et al., 2003). Briefly, 50µg of protein were incubated for 2h at 25˚C with
50µM of the 7-aminomethyl-4-coumarin (AMC)-labeled peptide Suc-Leu-Leu-ValTyr-AMC (for chymotrypsin-like activity), Boc-Leu-Arg-Arg-AMC (for trypsin-like
activity) or z-Leu-Leu-Glu-AMC (for caspase-like activity) in the absence or
presence of 10µM clasto-lactacystin-β-lactone (Enzo Life Sciences, Plymouth
Meeting, PA) or 50µM epoxomicin (for the trypsin-like activity). The different
activities of the 20S proteasome were calculated as the difference in
fluorescence intensity at 460nm between the samples without and with inhibitor
using an excitation wavelength of 380nm.
Total calpain activity was determined by a similar procedure using the
substrate Suc-Leu-Leu-Val-Tyr-AMC in 100mM KCl, 10mM CaCl2, 25mM Hepes
buffer pH 7.5, and carrying out the incubation in the absence or presence of 10
µg calpeptin (Hassem et al., 2006). To measure soluble (active) calpain activity,
membrane-bound calpain was removed prior to the assay by centrifugation at
10,000 g for 25 min.
Lysosomal proteolytic activity was also measured fluorometrically by
incubating cerebellar homogenates with 200µM z-Phe-Arg-AMC in 50 mM
sodium acetate (pH 5.5) for 30 min at 37˚C (Sitte et al., 2000).

52

3.3.4 Western blots
Proteins (5 µg) from cells or tissue homogenates were separated by SDS–
polyacrylamide gel electrophoresis on 10% gels and blotted to polyvinylidene
difluoride (PVDF) membranes. Blots then were incubated overnight at 4°C with
monoclonal antibodies against GFAP (1:2,000; Sigma), GAPDH (1:2,000;
Chemicon, Temecula, CA) or α-subunit of 20S proteasome (1:2,000; Enzo).
Membranes were rinsed three times in phosphate-buffered saline (PBS)
containing 0.05% Tween-20 and incubated for 2 h with horseradish peroxidase
conjugated-conjugated goat anti-mouse antibody (1:2,000; Sigma). Blots were
developed by enhanced chemiluminescence (ECL) using the Western Lightning
ECL™ kit from Perkin-Elmer (Boston, MA, USA).
Protein carbonyl groups were measured by western blot analysis using the
OxyBlot™ protein oxidation detection kit (Intergen Co., Purchase, NY) as
described earlier (Smerjac & Bizzozero, 2008). In brief, proteins (5 µg) were
incubated with 2,4-dinitrophenyl-hydrazine to form the 2,4-dinitrophenyl (DNP)
hydrazone derivatives. Proteins were separated by electrophoresis and blotted to
PVDF membranes as above. DNP-containing proteins were detected using rabbit
anti-DNP antiserum (1:500) and goat anti-rabbit IgG conjugated to horseradish
peroxidase (HRP) (1:2000).

3.3.5 Quantification of carbonylation levels in specific proteins
The extent of protein carbonylation was determined using a pulldown/western blot method (Bizzozero et al., 2006). Briefly, protein carbonyls
were biotinylated by reaction with biotin hydrazide in the presence of
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cyanoborohydride. A small aliquot of these protein homogenates was saved for
western blotting and the rest was used to isolate the biotinylated proteins using
streptavidin-agarose. Proteins were eluted from the beads with SDS-sample
buffer and analyzed by western blotting on 10% polyacrylamide gels. Blots were
probed with antibodies against individual protein species and developed by ECL
as described above. Films were scanned in a Hewlett Packard Scanjet 4890 and
the images were quantified using the NIH Image 1.63 imaging analysis program.
Band intensities from the total and streptavidin-bound fractions were used to
calculate the percentage of protein that is modified by carbonylation.

3.3.6 Immunohistochemical
cerebellum.

localization

of

poly-ubiquitinated

proteins

in

Accumulation of poly-ubiquitinated proteins in the cerebellum was assessed
by immunohistochemistry. To this end, cerebella from control and EAE animals
were fixed overnight in methacarn and then mounted in paraffin. Tissue was
sectioned in the sagital plane (6-µm thick) and mounted on Vectabond™-treated
slides (Vector Laboratories, Burlingame, CA, USA). Sections were deparafinized
with xylenes and a graded alcohol series, and then rinsed with PBS for 10 min.
Lesions were detected by staining with hematoxylin and eosin. The adjacent
slices were collected, rinsed three times with PBS, blocked with 10% (v/v) normal
goat serum and incubated overnight with the mixture of anti-polyubiquitin
antibody (1:200, mouse monoclonal; Enzo) and anti-GFAP antibody (1:200,
rabbit polyclonal; Dako, Carpinteria, CA). After removing the primary antibodies
with PBS containing 0.1% Triton X-100, the sections were incubated for 3 h with
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fluorescent conjugated secondary antibodies (Alexa Fluor® 488 and Alexa
Fluor® 647, Molecular Probes, Eugene, OR, USA). Slide-mounted sections were
scanned at a total magnification of 80X and images were imported into Image J
software to obtain optical density of polyubiquitin in GFAP immunoreactive cells
in cerebella. Briefly, the poly-ubiquitin or GFAP optical density was measured by
circling the whole GFAP immunoreactive cell. Three cells per slide and three
slides per animal were randomly chosen. In all cases, the background was
subtracted from the average density. The final data is presented as average
density of polyubiquitin or polyubiquitin divided by GFAP.

3.3.7 Statistical Analysis
Results were analyzed for statistical significance with ANOVA utilizing
GraphPad Prism® program (GraphPad Software Inc., San Diego, CA).

3.4 Results
3.4.1 Differentiation of C6 cells into astrocytes and induction of oxidative stress
with LPS
An in vitro study was designed to identify the major proteolytic system(s)
responsible for the removal of carbonylated proteins from astrocytes under
oxidative stress conditions. To this end, we first established a cell culture system
in which C6 glioma cells were differentiated into astrocytes by treatment with a
cyclic AMP analogue (Haghighat et al., 2000). As shown in Figure 3.1, treatment
of C6 cells with Bt2AMP/theophylline elevated GFAP expression already at 8 h of
incubation (Figure 3.1A-B). GFAP levels in these cells continued to increase until
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72 h. At this time cells displayed the morphological characteristics of astrocytes
(Figure 3.1C).
Differentiated astrocytes were then incubated with LPS (1µg/ml) for 24 h
to induce oxidative stress. LPS is a bacterial endotoxin and a generally accepted
inducer of pro-inflammatory responses (Kalmár et al., 2001). As expected, the
concentration of nitrite (a marker of nitric oxide production) in the medium was
significantly higher in LPS-treated astrocytes (Figure 3.2A). GSH levels in LPSstimulated astrocytes were reduced to 83% of control values (Figure 3.2B).
Surprisingly, the amount of protein carbonyls, another marker of oxidative stress,
was not increased in LPS-stimulated astrocytes Figure 3.2C). This observation
suggests that either the extent of oxidative stress is not enough to induce
extensive protein carbonylation or that the proteolytic machinery present in these
cells is sufficient to remove oxidized proteins as they are generated.

3.4.2 Proteasome inhibition leads to accumulation of carbonylated proteins in
cultured astrocytes
To identify the proteolytic system responsible for the removal of oxidized
proteins, control and LPS-stimulated astrocytes were incubated for 24 h in the
absence or presence of the proteasome inhibitor epoxomicin (Meng et al., 1999),
the lysosomal inhibitor NH4Cl (Brown et al., 1985) or the calpain inhibitor
calpeptin (Tsujinaka et al., 1988). To achieve maximal inhibition, these drugs
were used at concentrations between 20- and 200-fold higher than their
respective IC50. As shown in Figure 3.3, only epoxomicin causes the build-up of
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carbonylated proteins in both control and LPS-stimulated cells. These findings
suggest not only that the proteasome is responsible for removal of oxidized
proteins in vitro, but also that proteasomal proteolytic activity is more important
than the redox environment in determining the carbonylation status of proteins.
We next investigated whether the major oxidized proteins that accumulate
in the cerebellum of mice with chronic EAE (i.e. β-actin, β-tubulin and GFAP) are
also degraded by the proteasome in cultured astrocytes. Quantification of the
extent of carbonylation of individual proteins was performed using a pulldown/western blot procedure. To this end, protein carbonyl moieties from LPStreated astrocytes that had been incubated with or without epoxomicin for 24 h
were first converted into biotinylated residues by reaction with biotin-hydrazide.
Biotin-containing proteins were then isolated with streptavidin-agarose and
analyzed by western blotting employing antibodies against each of the three
polypeptides. As shown in Figure 3.4, the proportion of β-actin, β-tubulin and
GFAP present in the streptavidin-bound fraction increased significantly in the
epoxomicin-treated cells, indicating that these proteins are also degraded by the
proteasome. It is noteworthy that the molecular weight of oxidized proteins
present in the bound fraction is identical to those in the total fraction,
demonstrating that they do not contain attached ubiquitin moieties (8.5 kDa per
monomer). Thus, it is fair to conclude that degradation of the carbonylated forms
of β-actin, β-tubulin and GFAP, and likely those of most other proteins, is carried
out by the proteasome via an ubiquitin-independent mechanism.
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3.4.3 Proteasomal proteolytic activity is reduced in chronic EAE
After identifying the 20S proteasome as the proteolytic system responsible
for removal of oxidized proteins in cultured astrocytes, we sought to determine
whether or not the proteasome proteolytic activity is impaired in chronic EAE. To
this end, EAE in female C57BL/6 mice was induced by active immunization with
MOG35-55 peptide as described under Materials and Methods. Symptoms were
graded according to the following scale: 0, no symptoms; 1, tail weakness; 1.5,
clumsy gait; 2, hind limb paresis; 2.5, partial hind limb dragging; 3, hind limb
paralysis; 3.5, hind limb paralysis with fore limb paresis; 4, complete paralysis;
and 5, moribund. In this well-characterized EAE model, neurological symptoms
begin at 14 DPI (7 days after the boost with MOG peptide) reaching a peak at 30
DPI, and most animals remain ill (score 3.0-3.5) throughout the entire
experimental period (60 DPI) (Figure 3.5A). Acute disease was defined as having
clinical signs of EAE without any signs of improvement for at least three
consecutive days while chronic EAE was defined arbitrarily as animals that
remain in the stationary phase of the disease for 30 days (60 DPI). A complete
morphological description of the cerebellar pathology in this model, including the
histological and cellular distribution of carbonyls, has been presented in our
previous study (Zheng & Bizzozero, 2010a).
Aliquots of cerebellar homogenates from control and EAE mice, both at
the peak of the disease and in the chronic phase, were used to determine the
various proteolytic activities of the 20S proteasome. The chymotrypsin-like
activity, which is believed to be responsible for degrading oxidized proteins
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(Ferrington et al., 2005), was elevated in acute EAE and greatly reduced (~40%)
in chronic EAE relative to the controls (Figure 3.5B). This finding agrees with the
idea that decreased proteasomal activity is behind the accumulation of protein
carbonyls as disease progresses from the inflammatory (acute) to the
neurodegenerative (chronic) phase. A similar pattern was found for the
proteasome caspase-like activity (Figure 3.5C). The trypsin-like activity while
increased in acute EAE was surprisingly unchanged in chronic EAE (Figure
3.5D).
To establish if the changes in proteolytic activity observed during the
course of EAE was a consequence of variations in proteasome concentration, we
measured the relative levels of the 20S proteasome α-subunit by western blot
analysis. As depicted in Figure 3.6, the amount of proteasome α-subunit in acute
and chronic EAE was the same as those in the controls, suggesting that
decrease activity in the chronic phase of the disease may be due to enzyme
inactivation.
We also looked into the possibility that the proteolytic activity of the
lysosome and/or calpain may be decreased in chronic EAE. The activity of
cathepsin B, one of the major lysosomal proteases, was assayed with the z-PheArg-AMC peptide at acid pH. Using these conditions, the lysosomal proteolytic
activity was increased in chronic EAE as compared to control animals, while no
difference was observed between acute EAE and control mice (Figure 3.7A).
Neither the total (Figure 3.7C) nor the soluble (active) calpain activity (Figure
3.7B) in the cerebellum of affected animals was different from those of controls.
59

3.4.4 Carbonylated cytoskeletal proteins prepared from acute and chronic EAE
tissues are equally sensitive to proteasomal degradation in cell-free
system.
Another possibility that could explain the build-up of oxidized proteins in
chronic EAE is that the carbonylated species in the chronic phase are somehow
more resistant to proteolysis that those present in the acute phase. To address
this issue, we incubated cerebellar homogenates from acute and chronic EAE
mice with 20S proteasome in the absence or presence of the proteasome
inhibitor clasto-lactacystin-β-lactone. After 2h, the proportion of carbonylated βactin, β-tubulin and GFAP was determined using the pull-down/western blot
procedure described earlier. Since the results were the same for all three
proteins, only those corresponding to GFAP are presented herein (Figure 3.8).
The results clearly show that the proteolytic activity present in the tissue
homogenate itself is sufficient to degrade carbonylated GFAP from acute and
chronic EAE samples equally well. Addition of 20S proteasome did not produce
any significantly increase in the extent of proteolysis. In all cases, degradation of
carbonylated GFAP was prevented by addition of clasto-lactacystin--lactone,
indicating that proteolysis of oxidized proteins in this cell-free system, like in
cultured astrocytes, is indeed mediated by the 20S proteasome. The fact that
degradation of oxidized GFAP in this system takes place in the absence of added
ATP demonstrates once again that the mechanism does not involve
ubiquitination. In sum, these data support the notion that oxidized GFAP from
acute and chronic EAE are equally sensitive to degradation by the 20S
proteasome.
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3.4.5 Ubiquitinated proteins build-up in cerebellar astrocytes in chronic EAE
Since a significant proportion of the 20S catalytic particle is part of the 26S
proteasome we reasoned that the proteolytic activity of the latter, and thus the
ability to remove ubiquitinated proteins, might also be compromised in chronic
EAE. This possibility was explored by immunohistochemistry using a monoclonal
antibody that reacts with mono/poly-ubiquitinated proteins but not with free
ubiquitin. A strong and extensive poly-ubiquitin staining, the majority of which colocalizes with GFAP, was observed the cerebellum of chronic EAE but not acute
EAE mice (Figure 3.9). The intensity of poly-ubiquitinated proteins relative to that
of GFAP augmented three-fold in chronic EAE compared to the age-matched
control while there was no difference in this parameter between acute EAE and
its control. The accumulation of ubiquitinated proteins in cerebellar astrocytes of
chronic EAE mice demonstrates an impairment of proteasomal activity in this cell
type. Furthermore, this finding explains why the majority of carbonylated proteins
also accumulate within these cells (Zheng & Bizzozero, 2010a).

3.5 Discussion
We have previously shown that the proportion of carbonylated GFAP, βtubulin and β-actin is notably higher in chronic EAE mice than in acute EAE
animals (Zheng & Bizzozero, 2010a). Because oxidative stress is relatively low in
the chronic phase, we speculated either that the degradation system responsible
for removal of oxidized proteins becomes impaired as disease progresses or that
the carbonylated protein species from older animals are more resistant to
degradation. To investigate these two non-excluding possibilities, we first
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performed an in vitro study to identify the specific degradation system
responsible for the removal of carbonylated proteins. Using LPS-stimulated
astrocytes (the cell type where the majority of carbonyls accumulate in EAE) and
a number of protease inhibitors, we identified the 20S proteasome as the system
involved in the proteolysis of carbonylated proteins. This conclusion agrees with
studies carried out in other systems (Shringarpure et al., 2003; Divald & Powell,
2006). We then discovered that there is a marked reduction in the 20S
proteasome chymotrypsin-like activity in chronic EAE without significant changes
in the proteasome level. Moreover, based on studies in a cell-free system (Fig.
3.8), the possibility that oxidized cerebellar proteins from chronic EAE mice are
less susceptible to proteasomal degradation seems unlikely. Thus, we conclude
that the accumulation of carbonylated proteins in chronic EAE is probably the
result of the direct inhibition of proteasome’s proteolytic activity. The fact that
decreased proteasomal activity and increased protein carbonylation take place
primarily in the same cell type (i.e., astrocytes) further support such relationship.
It is clear, however, that only the reduction in protein carbonyl levels upon overexpression or activation of the 20S proteasome in chronic EAE animals will
demonstrate this conclusion.
Mammalian cells contain several proteolytic systems including the
lysosomal cathepsins, calcium-activated proteases (calpains) and the 20S/26S
proteasome (Grune et al., 2001). It has been shown that degradation of
carbonylated proteins is carried out in an ATP- and ubiquitin-independent
manner by the 20S proteasome, which selectively recognizes and digests
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partially unfolded (denatured) oxidized proteins (Rivett, 1985; Pacifici et al., 1993;
Grune et al., 1995). However, the calcium-dependent cysteine protease calpain
has been also shown to preferentially degrade oxidized neurofilament over nonoxidized protein in cell-free systems (Troncoso et al., 1995). Furthermore, there
is some evidence that moderately or heavily oxidized proteins are taken up by
lysosomes, where in some cases are incompletely degraded and accumulate in
the form of lipofuscin-like, autofluorescent aggregates (Dunlop et al., 2009). Our
study clearly shows that degradation of carbonylated proteins in LPS-treated and
untreated astrocytes is carried out by 20S proteasome as neither calpain not
lysosome inhibition led to an accumulation of the oxidized proteins in the 24hincubation period. Furthermore, calpain and cathepsin B activities were not
impaired in chronic EAE, where there is a build up of carbonylated species. The
increased lysosomal cathepsin B activity in the cerebellum of chronic EAE mice
is noteworthy. As suggested by Pandley et al., (2007), an increase in the
lysosomal degradation machinery when the proteasome system is not
functioning may represent a compensatory mechanism for intracellular protein
degradation.
The 20S proteasome particle is composed by two outer (alpha) and two
inner (beta) rings. Three of the β subunits carry the proteolytic activity, classified
as caspase-like (β1), trypsin-like (β2), and chymotrypsin-like (β5), which cleaves
after acidic, basic and hydrophobic amino acids, respectively (Coux et al., 1996).
Of these, the β5 subunit is believed to be responsible for the degradation of
oxidized (carbonylated) proteins (Ferrington et al., 2005). Thus, the decrease in
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20S proteasome chymotrypsin-like activity in chronic EAE mice is consistent with
the accumulation of carbonylated proteins previously reported in the same
animals

(Zheng

&

Bizzozero,

2010a).

Interestingly,

this

decrease

in

chymotrypsin-like activity is not due to a reduction in the number of 20S particles
since -subunit expression was unaltered in the disease. Furthermore, the
various activities were not equally affected throughout the course of the disease.
For instance, only chymotrypsin-like and caspase-like activities were reduced in
chronic EAE while only chymotrypsin-like and trypsin-like activities were
augmented in acute EAE. Based on these findings, it is fair to speculate that, as
disease progresses, there is a change in the proportion of individual β-subunits
within the catalytic core particle and/or that the enzyme activities are specifically
inhibited. The increase in the activity associated with β2 and β5 subunits during
the inflammatory phase of disease might be due to the β-interferon-triggered
replacement of these catalytic subunits by inducible subunits iβ1, iβ2 and iβ5 to
form the so-called immunoproteasome, which exhibits higher chymotrypsin-like
and trypsin-like activities and lower caspase-like activity (Gaczynska et al., 1993).
Yet this mechanism would not explain the reduction in caspase-like and
chymotrypsin-like activity observed in the chronic animals. In this regard,
inhibitory posttranslational modifications (e.g., oxidation) or the increased
presence of endogenous inhibitors such as cross-linked proteins may explain our
findings. For example, oxidative injury to the heart during ischemia-reperfusion
injury has been found to induce selective rather than global inhibition of
proteasomal activity (Bulteau et al., 2001a). Furthermore, specific subunits of the
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20S proteasome are targeted for modification by the lipid peroxidation product 4hydroxy-2-nonenal (4-HNE) (Farout et al., 2006), the glycoxidation product
glyoxal (Bulteau et al., 2001b) and β-ketoaldehydes (isoketals) (Davies et al.,
2002). Whether similar types of modifications also take place in EAE is not
known. However, using antibodies against the major reactive carbonyl species,
we have not been able to detect HNE, MDA or acrolein-adducts in EAE tissue
(Zheng & Bizzozero, 2010a). A more likely modification of β-subunits could be
the direct carbonylation of its amino acid residues as shown for those in
proteasomes of hepatocellular carcinoma HepG2 cells under oxidative stress
conditions (Kessova & Cederbaum, 2005). Beside direct inactivation of the
proteasome by oxidation/carbonylation, 4-HNE cross-linked proteins (Friguet et
al., 1994) and lipofuscin/ceroid fluorescent pigments (Sitte et al., 2000) have
been implicated in the inhibition of proteasome activity. An additional and still
unexplored possibility might be the inactivation of proteasome activity by specific
autoantibodies. Interestingly, antibodies against several proteasomal subunits
have been detected in serum and CSF from MS patients (Mayo et al., 2002). It
will be important to know if proteasome autoantibodies occur also in animals with
chronic EAE and whether they indeed cause enzyme inhibition.
While novel, the discovery that proteasome activity is decreased in chronic
EAE is not entirely unexpected. Impaired proteasomal function has been
reported in several chronic neurodegenerative diseases including Alzheimer’s
disease (Keller et al., 2000) Parkinson’s disease (McNaught et al., 2003) and
Huntington’s disease (Seo et al., 2004). Furthermore, preliminary studies in our
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laboratory suggest that this may be also the case in MS, where accumulation of
both carbonylated proteins (Bizzozero et al., 2005) and ubiquitin-conjugates
(Giordana et al., 2002) has been already described. The pathophysiological
consequences of decreased proteasomal activity in chronic EAE as well as in
classical neurodegenerative disorders are unknown. The functional impact
resulting from the accumulation of a number of ubiquitinated, misfolded,
aggregated and oxidized proteins, along with reduced degradation of various
signaling and pro-apoptotic molecules, is likely widespread and difficult to predict.
Yet decreased proteasomal activity is likely pathogenic and a contributor to
neurodegeneration in chronic EAE. This notion is based mostly on experiments
linking proteasomal inhibition to axonal damage (Korhonen, 2004), the
development

of

pro-inflammatory

responses

via

up-regulation

of

cyclooxygenase-2 and prostaglandin E2 (Rockwell et al., 2000) and apoptosis of
neurons and oligodendrocytes via mitochondrial dysfunction (Goldbaum et al.,
2006).
Finally, it is puzzling why proteasomal inhibition and accumulation of both
oxidized and ubiquitinated proteins occur mostly in astrocytes. One possibility is
that the ROS and other molecules produced upon inflammatory activation of
astrocytes (Keller et al., 1999) are capable of damaging the 20S proteasome.
Since astrocytes are more resistant than neurons and oligodendrocytes to the
cytotoxic consequences of proteasomal inhibition (Tsuji et al., 2005; Goldbaum et
al., 2006), it is also possible that as disease progresses damaged neurons and
oligodendrocytes die and are removed from the tissue leaving behind astrocytes
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loaded with undigested proteins. Studies in our laboratory are underway to test
these possibilities.
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Figure 3.1 Differentiation of C6 glioma cells into astrocytes. C6 cells were
incubated with Bt2AMP/theophylline for up to 72h as described in “Material and
Methods”. Levels of GFAP and GAPDH were determined by western blot (panel
A). Band intensities were measured by scanning densitometry and were used to
calculate the GFAP/GAPDH ratio (panel B). Values represent the mean ± SEM of
3 experiments. Asterisks denote values that are statistically different (p<0.05)
from non-stimulated control cells. NS, not significant. Panel C shows a double
immunofluorescence picture of untreated and Bt2AMP/theophylline-treated C6
cells. GFAP and nuclear (DAPI) staining are shown in green and blue,
respectively. Bar= 50µm. Note that at 72 h, C6 cells are not longer round and flat,
but show large amount of GFAP-positive processes that are characteristics of
astrocytes.
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Figure 3.2 Levels of nitrosative/oxidative stress markers in control and LPSstimulated astrocytes. Astrocytes were stimulated with 1µg/ml of LPS. After 24h,
the levels of nitrite in the medium (panel A), and those of GSH (panel B) and
protein carbonyls (panel C) in the cells were determined as described under
“Materials and Methods”. Values represent the mean ± SEM of 3 experiments.
*p<0.05. NS, not significant.

69

Figure 3.3 Only the proteasome inhibitor epoxomicin causes a build-up of
carbonylated proteins in cultured astrocytes. Astrocytes were incubated in the
presence or absence of LPS with/without a proteasome inhibitor (epoxomicin), a
lysosomal inhibitor (NH4Cl) and a calpain inhibitor (calpeptin) as described in
“Materials and Methods”. After 24 h, protein carbonyl levels were determined by
oxyblot analysis (Panel A). The intensity of each lane of the oxyblot was
determined by scanning densitometry and divided by that of the coomassie blue
stained membrane to correct for differences in gel loading (panel B). Values
represent the mean ± SEM of 3 experiments. *p<0.05.
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Figure 3.4 The proportion of carbonylated GFAP, β-actin and β-tubulin in LPSstimulated astrocytes increases upon incubation with the proteasome inhibitor
epoxomicin. LPS-treated astrocytes were incubated in the absence or presence
of epoxomicin. After 24 hours, carbonylated proteins were converted into
biotinylated proteins and were isolated using streptavidin-agarose as described
in “Materials and Methods”. Aliquots of the starting material (total) and the
streptavidin-purified fraction (bound) were separated on SDS-gels and
transferred to PVDF membranes. Blots were probed with antibodies against βactin, β-tubulin and GFAP, and were developed by ECL (panel A). Densitometric
scans were obtained to calculate the proportion of the various carbonylated
species in epoxomicin-treated and untreated activated astrocytes (Panel B).
Values represent the mean ± SEM of 3 experiments. *p<0.05, **p<0.01.

71

Figure 3.5 The chymotrypsin-like and caspase-like activities of the 20S
proteasome are significantly reduced in chronic EAE. The disease was induced
in C57BL/6 female mice by active immunization with MOG35-55 peptide as
described in “Materials and Methods”. Animals were monitored daily for signs of
clinical disease and scored as indicated in the text (panel A).

Aliquots of

cerebellum homogenates from control and EAE mice were used to determine the
chymotrypsin-like (panel B), caspase-like (panel C) and trypsin-like (panel D)
activity of the 20S proteasome as described in “Materials and Methods”. Values
represent the mean ± SEM of 4-10 experiments. *p<0.05; FU, fluorescence units.
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Figure 3.6 The amount of 20S proteasome is not altered in chronic EAE. Proteins
from control and EAE cerebella were separated on SDS-gels and transferred to
PVDF membranes. Blots were probed with antibodies against the constitutive αsubunit, and were developed by ECL (panel A). The relative levels of the
proteasome were calculated by dividing the α-subunit band intensity on the
western blot by that of the commassie blue stained lane. Values are the mean ±
SEM of 5-8 experiments. NS, not significant.
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Figure 3.7 Neither cathepsin B nor calpain activity is decreased in chronic EAE.
Aliquots of cerebellum homogenates from control and EAE mice were used to
determine cathepsin B and total/soluble calpain activity as described in “Material
and Methods”. Values are the mean ± SEM of 4-6 experiments. * p<0.05; FU,
fluorescence units.
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Figure 3.8 Carbonylated GFAP from acute and chronic EAE animals are
sensitive to proteasomal degradation in a cell-free system. Cerebellum
homogenates from acute and chronic EAE mice (200 µg protein) were incubated
with 0.5 µg of 20S proteasome (Sigma) in the absence or presence of 2 µg
clasto-lactacystin-β-lactone (Enzo Life Sciences). After 2 h, carbonylated proteins
were isolated using the pull-down procedure described in “Materials and
Methods”. A representative western blot of the total and bound fractions
developed with an antibody against GFAP is shown in panel A. Densitometric
scans were obtained to calculate the proportion of carbonylated GFAP in the
various conditions (Panel B). The 20S chymotrypsin-like activity in the
homogenates increased ~12-fold upon addition of 20S proteasome and was
reduced by ~90% in the presence of clasto-lactacystin-β-lactone. Values
represent the mean ± SEM of 4 experiments. *Significantly different (p<0.05)
from non-incubated condition; #Significantly different (p<005) from the 20S
proteasome-treated condition.
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Figure 3.9 Ubiquitinated proteins build-up inside cerebellar astrocytes of mice
with chronic EAE. Double immunofluorescence analysis was performed as
described in “Methods and Materials”. Green channel is for GFAP while red
channel is for mono/poly-ubiquitinated proteins. Immunofluorescence images
show extensive poly-ubiquitin staining only in chronic EAE. The majority (~73%)
of the cells containing ubiquitinated proteins are also GFAP+. Bar graphs depict
the quantification of poly-ubiquitin immunoreactivity and poly-ubiquitin divided by
GFAP. *p<0.01
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4.1 Abstract
We have previously shown that carbonylated (oxidized) proteins accumulate
in the cerebral white matter (WM) and gray matter (GM) of patients with multiple
sclerosis (MS). While oxidative stress is necessary for carbonyl generation, it is
the failure of degradation systems that ultimately leads to the build-up of
carbonylated proteins within tissues. In this study, we determined the activity of
the 20S proteasome and other proteolytic systems in the cerebral WM and GM of
13 MS patients and 13 controls. We report that the activities of the three
peptidases of the 20S proteasome (i.e. chymotrypsin-like, caspase-like and
trypsin-like) in both MS-WM and MS-GM are greatly reduced without a decrease
in the amount of proteasome. Furthermore, not only carbonylated proteins but
also proteins containing Lys-48 poly-ubiquitin accumulate in MS tissues,
indicating failure of the 26S proteasome as well. Interestingly, the amount of 20S
proteasome subunits (β1, β2, and β5) where the catalytic activities reside are not
diminished in MS. Levels of the regulatory caps PA28α and PA700 are also
lower in MS than in controls, indicating that the activity of the more complex
proteasomes may be reduced further. Finally, the activities of other proteases
that might also remove oxidized proteins (calpain, cathepsin B, mitochondrial
LONp) are not lessened in MS. Together, these studies suggest that direct
inactivation of proteolytic centers in the 20S particle and/or the presence of
specific inhibitors lead to proteasomal dysfunction in MS.
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4.2 Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the human CNS,
which

is

characterized

by

perivascular

inflammation,

demyelination,

oligodendrocyte death and axonal degeneration (1). Pathologically, the CNS in
MS patients contains well-demarcated regions of myelin loss and increased
astrogliosis called plaques that are surrounded by normal-appearing white matter
(NAWM) (2). While most of the pathology in chronic MS is observed in the plaque,
cellular and chemical abnormalities are also found in the NAWM and the normalappearing gray matter (NAGM) as demonstrated in recent imaging (3, 4) and
biochemical studies (5, 6).
Like many other chronic neurological disorders, MS is accompanied by a
substantial amount of oxidative damage, which seems to play a role in disease
pathogenesis (7). We have previously shown that protein carbonyls, the major
oxidative modification in chronic disorders, accumulate in the NAWM and NAGM
of MS patients (6) with GFAP, β-tubulin, β-actin and the neurofilaments as the
major oxidized species (8). More recent studies from our laboratory have
discovered that protein carbonyls are also elevated in experimental autoimmune
encephalomyelitis (EAE), a widely used animal model of MS (9, 10).
Carbonylation can lead to loss of protein function, the formation of insoluble
aggregates and/or metabolic instability, all processes that likely result in cell
damage (11). Because of their toxic nature, the concentration of carbonylated
proteins within cells is normally kept very low, which is achieved through the
action of efficient proteolytic systems that preferentially digest oxidized proteins
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(11). This has led to the idea that while oxidative stress is clearly necessary for
the induction of protein carbonyls, it is the failure of the proteolytic activities that
ultimately leads to the build up of oxidized proteins within tissues.
Mammalian cells contain several major proteolytic systems including the
lysosomal cathepsins, the calcium-activated calpains and the 20S/26S
proteasomes, all of which could potentially remove oxidized proteins (12).
However, various cell-culture studies that utilized protease inhibitors have
identified the 20S proteasome as the system responsible for removal of most
oxidized protein species (13,14). The 20S proteasome is a barrel-shaped
structure that is made of two outer heptameric rings of α subunits and two inner
heptameric rings of β subunits (15). Three of the β subunits carry the proteolytic
activity, classified as caspase-like or peptidyl glutamyl-peptide hydrolytic (β1),
trypsin-like (β2), and chymotrypsin-like (β5), which cleave after acidic, basic and
hydrophobic amino acids, respectively (16). Of these, the β5 subunit is believed
to be responsible for the degradation of oxidized (carbonylated) proteins (17).
The peptidase activity of the 20S proteasome can be increased by two different
types of regulatory complexes that bind to the terminal rings of this particle.
These are the 11S regulator (PA28) and the 19S (PA700) regulatory complex,
which form the 11S-20S proteasome and the 26S proteasome, respectively (18).
A number of proteasome inhibitors, including the hsp90, PI31 and PR39, have
been also described although their precise physiological role is currently
unknown (19).
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The objective of the present study was to determine whether the various
proteolytic activities of the 20S proteasome are altered in MS. The results clearly
show that the enzymatic activities of the three peptidases of the 20S proteasome
are greatly reduced in both the white and gray matter of MS patients without
significant decrease in the total amount of proteasome. Furthermore, the levels of
the 20S proteasome β subunits where the peptidolytic activities reside are not
affected in the diseased specimens. We also found that the amount of the
regulatory caps PA28α and PA700 are lower in MS than in control samples,
indicating that the activity of the larger proteasomes (i.e. 26S, 11S-20S and
hybrid 19S-20S-11S) may be reduced to an even larger extent. Collectively,
these studies suggest that the direct inactivation of proteolytic centers in the 20S
particle and/or the presence of specific inhibitors are the most likely cause for
impaired proteasome function in MS and the ensuing build-up of carbonylated
proteins. This notion was strengthen by the finding that the other enzymatic
system that might also aid in the removal of oxidized protein, including calpain,
lysosomal proteinases and the mitochondrial LON protease, are not decreased in
MS.

4.3 Materials and Methods
4.3.1 Tissue Specimens
Tissue specimens were obtained from the Rocky Mountain MS Center
(Englewood, CO) and from the Human Brain and Spinal Fluid Resource Center
(Los Angeles, CA) and were stored at -80˚C until use. A total of 26 brain
specimens including 13 control and 13 MS tissues were analyzed. In all cases
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the diagnosis of MS was based on clinical history, neurological examination and
pathological analysis. Frozen tissue from control and pathological samples was
thawed and a small piece (~50 mg) of white matter (WM) was carefully dissected
so that it did not include visible plaques. Normal-looking gray matter (GM) pieces
were selected from cortical areas based also on gross examination. Tissues
were immediately homogenized in PEN buffer (20 mM sodium phosphate, pH 7.5,
1 mM EDTA, and 0.1 mM neocuproine) containing 2 mM 4,5 dihydroxy-1, 3benzene disulfonic acid and 1 mM dithiothreitol (DTT) as antioxidants. Protein
homogenates were stored at -20°C until use. Protein concentration was
assessed with the Bio-Rad protein assay (Bio-Rad Laboratories; Hercules, CA)
using bovine serum albumin as standard.

4.3.2 Protease activity assays
The various proteolytic activities of the 20S proteasome were determined in
cerebral homogenates from control and MS patients using fluorescence assays
(20). Briefly, 50µg of protein were incubated for 2h at 25˚C with 50µM of the 7aminomethyl-4-coumarin (AMC)-labeled peptide Suc-Leu-Leu-Val-Tyr-AMC (for
chymotrypsin-like activity), Boc-Leu-Arg-Arg-AMC (for trypsin-like activity) or zLeu-Leu-Glu-AMC (for caspase-like activity) in the absence or presence of 10µM
clasto-lactacystin-β-lactone (Enzo Life Sciences, Plymouth Meeting, PA) or 50µM
epoxomicin (for the trypsin-like activity). The different activities of the 20S
proteasome were calculated as the difference in fluorescence intensity at 460nm
between the samples without and with inhibitor using an excitation wavelength of
380nm.
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Total calpain activity was determined by a similar procedure using the
substrate Suc-Leu-Leu-Val-Tyr-AMC in 100mM KCl, 10mM CaCl2, 25mM Hepes
buffer pH 7.5, and carrying out the incubation in the absence or presence of 0.4
µg/µl calpeptin (21). To measure soluble (active) calpain activity, membranebound calpain was removed prior to the assay by centrifugation at 10,000 g for
25 min.
Lysosomal proteolytic activity was also measured fluorometrically by
incubating cerebellar homogenates with 50µM z-Phe-Arg-AMC (Enzo) in 100 mM
sodium acetate (pH 5.5) for 2h at 37˚C (22).

4.3.3 Western blot analysis
Proteins (5 µg) from tissue homogenates were separated by SDS–
polyacrylamide gel electrophoresis on 10% or 12% gels and were blotted to
polyvinylidene difluoride membranes. Blots were then incubated overnight at 4°C
with antibodies against Lys-48 poly-ubiquitin chain (1:2,000; Millipore Corp.,
Billerica, MA), 20S proteasome α-subunits (α1-3/α5-7; 1:2,000; Santa Cruz
Biotechnology, Santa Cruz, CA), β1, β2 and β5 subunits (1:1,000; Enzo), PA28α
(1:1,000, Enzo), 19S proteasome Rpt4 (1:1,000, Enzo); µ-calpain (1:1,000; Cell
Signaling Technology, Boston, MA), cathepsin B (1:1,000; EMD Biosciences,
San Diego, CA) and LONp1 protease (1:2,000; Proteintech Group Inc, Chicago,
IL). Membranes were rinsed three times in phosphate-buffered saline solution
containing 0.05% Tween-20 and were incubated for 2 h with horseradish
peroxidase conjugated-conjugated anti-mouse antibody (1:2,000; Sigma) or anti-
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rabbit antibody (1:2,000; Sigma). Blots were developed by enhanced
chemiluminescence (ECL) using the Western Lightning ECL™ kit from PerkinElmer (Boston, MA). Films were scanned in a Hewlett Packard Scanjet 4890 and
the images were quantified using the NIH Image 1.63 imaging analysis program.
Band intensities were normalized by the amount of coomassie blue stain in the
respective lanes.

4.3.4 Statistical Analysis
Results were analyzed for statistical significance by t-test utilizing the
GraphPad Prism® program (GraphPad Software Inc., San Diego, CA).

4.4 Results
4.4.1 Proteasomal peptidase activities are decreased in MS-WM and MS-GM
The age of the patients at the time of death, gender, post-mortem interval
(PMI) and the pathological diagnosis are shown in Table I. Age of controls and
MS patients ranges from 34 to 80 years and from 33 to 83 years, respectively.
The control group has 7 men/6 women and the MS group 4 men/9 women. PMI
intervals are variable, 4h-20h for controls and 2h-25h for MS patients. Within
each group (i.e. MS and controls) there was no discernible correlation between
the biochemical parameters measured and either age, sex or PMI. Thus, the
average values in the MS and control specimens were directly compared without
segregation in subcategories.
Aliquots of cerebral homogenates from MS-GM, MS-WM and their
respective controls were used to determine the various proteolytic activities of the
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20S proteasome (Figure 4.1). The chymotrypsin-like activity is greatly reduced in
both NAWM and NAGM of MS patients representing 56% and 38% of control
values, respectively (panel A). A similar pattern was found for the caspase-like
activity in MS-NAWM and MS-NAGM, which decreased by 61 % and 60 % of
their respective controls (panel B). Values for the trypsin-like activity are
generally more disperse but a significant decreased in both the WM and GM of
diseased patients is nonetheless observed (panel C).
Since a significant proportion of the 20S catalytic particle is part of the 26S
ubiquitin-dependent proteasome, we reasoned that the proteolytic activity of the
latter, and thus the ability to remove ubiquitinated proteins, might also be
compromised in MS. This possibility was explored by western blot analysis using
an antibody that binds only poly-ubiquitin chains linked through the Lys-48
residue in ubiquitin. Lys-48 linked poly-ubiquitin chains are most commonly
associated with proteins targeted for proteasomal degradation (23). As shown in
Figure 4.2, several proteins containing Lys-48 poly-ubiquitin chains accumulate
in the WM and GM of MS patients relative to controls. These data indicate that
impairment of the 26S proteasome is also taking place in MS.

4.4.2 Levels of 20S proteasome α, β1, β2 and β5 subunits are not reduced in
MS tissue.
To establish if the decreased proteasomal activity observed in MS patients
is due to reduction in proteasome concentration or a change in the proportion of
the catalytic subunits, we measured the relative levels of the constitutive 20S

89

proteasome α subunit and those of each of the three protease-containing
subunits (i.e. β1, β2 and β5) by western blot analysis. As depicted in Figure 4.3,
the amount of 20S proteasome α subunit in MS-GM is the same as those in the
control group while there is a small increase in the WM of MS patients relative to
the control. Furthermore, the relative amounts β1, β2, and β5 subunits in the MSWM and MS-GM are either increased or unchanged when compared to their
respective controls (Figure 4.4). These data indicate that diminished proteasome
peptidase activity in MS is likely due to enzyme inactivation rather than to downregulation of enzyme proteins or reduced proteasome levels.

4.4.3 PA28α and PA700 levels are also diminished in MS.
The 20S proteasome may associate with the PA28 and PA700 regulators,
which are known to increase the proteolytic activity of the core particle (18).
There are three PA28 (11S) homologues, named α, β and γ. The α and β
subunits form a heteroheptamer while the γ subunit forms a homoheptamer that
is confined to the cell nucleus. The PA28β subunit is virtually absent from the
brain (19) but the α subunit is present and can assemble to form a PA28α
homoheptamer that has also the capacity to activate the 20S proteasome (24).
For this reason we decided to assess the levels of PA28α in MS and controls
samples. The results show a decrease of ~50% in the amount of 11S α subunit
in the MS-WM and MS-GM with respect to their controls (Figure 4.5A). The
relative levels of PA700 (19S) in MS and control homogenates were determined
also by western blot analysis employing an antibody that recognizes the
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Rpt4/S10b subunit (ATPase subunit) in this activator. The results clearly show a
reduction in PA700 (19S) levels only in the MS-WM (Figure 4.5B). It is important
to note that the reduced peptidolytic activities of the 20S proteasome in MS are
not a consequence of decreased levels of the activators PA28α and PA700,
since under the incubation conditions used in this study (i.e. without ATP or
magnesium ions and in the presence of 0.03% SDS) these caps are not attached
to the catalytic particle (25). In vivo, however, these regulators may be largely
bound to the 20S proteasome, suggesting that the activity of larger proteasomes
(i.e. 26S, 11S-20S and hybrid 19S-20S-11S) in MS may be reduced more than
that of the free 20S particle.

4.4.4 Calpain activity and expression are significantly upregulated in MS brains
The activities/levels of the three other proteolytic systems that might
potentially

remove

oxidized

proteins

(calpain,

lysosomal

cathepsins,

mitochondrial LON protease) were also determined in control and MS tissues.
Calpain is normally present as a membrane-bound pro-enzyme containing an
80kDa catalytic subunit that undergoes auto-proteolytic cleavage upon calcium
activation, thus releasing the 75-kDa active calpain into the cytosol (26). As
shown in Fig. 6A-B, the total and the soluble (active) calpain activity are elevated
in both the WM and GM of MS patients relative to their controls. Levels of total
calpain-1 (µ-calpain) were determined in the brain homogenates from MS and
control patients by western blotting. As depicted in Fig. 6C-D, total calpain levels
in the MS-WM and MS-GM were increased by 54% and 67%, respectively.
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These data indicate that the enhancement in calpain activity in MS tissues is
mostly due to an increase in the amount of enzyme.

4.4.5 Lysosomal proteolytic activity is slightly increased in MS gray matter
The proteolytic activity of the lysosome was also tested in MS patients. The
activity of cathepsin B, one of the major lysosomal proteases, was assayed with
the z-Phe-Arg-AMC peptide at acid pH. Measured under these conditions, the
lysosomal proteolytic activity in MS-WM and MS-GM increases by 40% and 38%
(Figure 4.7A). Levels of the 31kDa form of cathepsin B, as determined by
western blot analysis, are mostly unchanged in MS-WM and MS-GM relative to
their controls (Figure 4.7 B-C).

4.4.6 Levels of Lon protease are unaltered in MS
Lon is a proteasome-like protease localized in mitochondrial matrix and
responsible for the removal of oxidized proteins within this organelle (27).
Therefore, it is unlikely that a deficiency in the activity of the Lon protease in MS
would result in the accumulation of carbonylated cytoskeletal proteins that we
have observed (8). Nonetheless, since Lon protease levels are known to
decrease during aging and in several CNS disorders (28), we sough to
investigate its potential role in MS. As shown in Fig. 8, western blot analysis
clearly shows that the amount of this protease in both MS-WM and MS-GM are
the same as that in control specimens.
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4.5 Discussion
In this study we report that the peptidase activities present in the β1, β2 and
β5 subunits of the 20S proteasome are greatly reduced in both the WM and GM
of MS patients as compared to controls. Based on the quantification of the
constitutive 20S proteasome α subunit by western blotting, we conclude that
changes in proteasomal activity are not due to a decline in the number of 20S
proteasome particles. More importantly, altered activities are not the result of
decreased levels of these subunits (Figure 4.4). Indeed, the amount of the β1
and β2 subunit is increased in both MS-WM and MS-GM, perhaps as a result of
compensatory mechanisms. Altogether these findings suggest that the activity of
these proteases in MS are inhibited, a phenomenon that we have recently also
observed in the chronic phase of MOG35-55 peptide-induced EAE (29). Levels of
the activators PA28α and PA700 are also lessened in the CNS of MS patients,
indicating that the catalytic efficiency of the larger proteasome particles are also
affected in this disorder.
Several posttranslational modifications of the 20S subunits that are capable
of reducing proteasomal activities have been discovered in oxidative stress
paradigms. For example, proteasome activity can be impaired by direct
carbonylation (30) or by modification with 4-hydroxy-2-nonenal (31), acrolein (32),
glyoxal (33), γ-ketoaldehydes (isoketals) (34) and nitric oxide (35). Direct
inactivation of the proteasome by 4-HNE cross-linked proteins (36) and
lipofuscin/ceroid fluorescent pigments (22) have been also implicated in the
inhibition of the 20S proteasome. An additional and still unexplored possibility
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might be proteasome inactivation by specific autoantibodies. Interestingly,
antibodies against several proteasome subunits have been detected in serum
and CSF from MS patients (37). It will be important to know if proteasome
autoantibodies are also present in the diseased brain and are indeed capable of
causing enzyme inhibition. Finally, the presence of endogenous negative
regulators such as hsp90, PI31 and PR39 (19) cannot be ruled out as the
underlying cause for proteasomal impairment in MS. Studies are underway in this
laboratory to identify potential inhibitors and the role of other regulators (e.g.
PA200) using both cell extracts and purified proteasome particles from MS brain
samples.
While impaired proteasomal activity has been reported in several
neurodegenerative diseases, such as Alzheimer’s disease (38), Parkinson’s
disease (39) and Huntington’s disease (40), this is the first study to demonstrate
proteasome dysfunction in a chronic human demyelinating disorder. Whether an
identical mechanism causes proteasome dysfunction in MS and the other
neurodegenerative disorders is presently unclear. Yet, it is noteworthy that in all
of these diseases the failure of the peptidase activities is not related to low levels
of proteasome particles or their catalytic subunits. The pathophysiological
consequences of decreased proteasomal activity in chronic MS as well as in
classical neurodegenerative disorders are unknown. The structural and functional
impact resulting from the accumulation of a number of ubiquitinated, misfolded,
aggregated and oxidized proteins, along with reduced degradation of various
signaling and pro-apoptotic molecules, are likely widespread and difficult to
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predict. However, decreased proteasomal activity is likely to be pathogenic and a
contributor to neurodegeneration in MS. This notion is based mostly on
experiments linking pharmacological inhibition of the proteasome catalytic core to
axonal damage (41), the development of pro-inflammatory responses via upregulation of cyclooxygenase-2 and prostaglandin E2 (42) and apoptosis of
neurons and oligodendrocytes via mitochondrial dysfunction (43), all of which are
characteristics of chronic MS.
There is general agreement that oxidized proteins are degraded by the 20S
proteasome via an ATP-independent mechanism (13,14, 44-46). However, there
have been some reports suggesting that other proteases may be also involved in
the degradation of carbonylated polypeptides. For example, the calciumdependent cysteine protease calpain has been found to preferentially degrade
oxidized neurofilaments over the non-oxidized protein forms in cell-free systems
(47) and there is some evidence that heavily oxidized proteins can be taken up
by lysosomes, where in some cases are incompletely degraded and accumulate
in the form of lipofuscin-like, autofluorescent aggregates (48). Furthermore, in
epithelial cells some of the 4-hydroxynonenal-modified proteins are degraded in
the lysosome via an ubiquitin-dependent mechanism (49). Due to these
observations, we felt compelled to determine the enzymatic activities of these
proteolytic systems in MS. In our study, we found that both the total and soluble
calpain activities are increased in MS patients. Elevation of total calpain activity
seems to be due to an increase in its translational expression. Interestingly,
calpain activity and expression is not only increased MS-WM, as reported earlier
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(26), but also in the MS-GM, suggesting that extensive calcium dysregulation
also occurs in this CNS area. We also found that the activity of cathepsin B, the
major lysosomal protease, is elevated in MS. As suggested by Pandley et al. (50),
an increase in the lysosomal degradation machinery when the proteasome
system is not functioning may represent a compensatory mechanism for
intracellular protein degradation. Finally, the relative amount of the Lon protease,
an enzyme that specifically degrades oxidized mitochondrial proteins by an ATPstimulated mechanism (27, 28), was unaltered in MS. In sum, of the several
proteolytic systems studied in post-mortem MS brains only the proteasome was
found to be impaired. Proteasome failure explains the accumulation of both
carbonylated proteins (6) and ubiquitin-conjugates (51; this study) in chronic MS
tissue.
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Table 4.1 Brain samples from control and MS patients

Sample

Age
(years)

Gender

PMI
(hours)

Pathological diagnosis

M
M
M
F
M
M
F
F
F
F
M
F
M

uk
4
9
19
10
14
20
12
12
5
14
15
11

Acute pancreatitis; Pneumonia
Metastatic lung cancer
Colon cancer
Lymphoma
Lung Cancer
Lymphoma
Congestive heart failure
COPD
Pancreatic cancer
Pneumonia
Metastatic lung cancer
Liver cancer
Renal cancer

F
F
M
F
F
F
M
F
F
M
M
F
F

3
4
5
2
3
16
24
25
3
3
6
16
3

Chronic/active MS; Hydrocephalus
Relapsing/remitting MS
Diffuse periventricular demyelination
Chronic/active MS
Active severe MS
Chronic/active MS
Chronic/active MS
Chronic progressive MS
Chronic MS/optic neuritis
Chronic/active MS
Chronic progressive MS
Chronic/active MS
Chronic MS

Control
1
34
55
2
58
3
4
59
5
68
6
71
7
72
8
73
9
74
10
74
11
74
12
75
13
80
Multiple Sclerosis
33
1
2
36
3
37
4
39
5
40
47
6
7
54
8
57
9
58
10
61
11
65
12
70
13
83
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Figure 4.1 - Proteasome peptidase activities are greatly reduced in MS. Aliquots
of the cerebral homogenates from control and MS patients were used to
determine the chymotrypsin-like (A), caspase-like (B) and trypsin-like activity (C)
of the 20S proteasome using specific fluorescent peptides as described in
“Materials and Methods”. Enzyme activity values are expressed as fluorescence
units (FU) / hour / µg protein. Each point represents a patient and the horizontal
bar is the average. *p<0.05, **p<0.01, ***p<0.005. Open circles, control WM;
closed circles, MS WM; open triangles, control GM; closed triangles, MS GM.
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Figure 4.2 - Proteins containing Lys-48-linked poly-ubiquitin accumulate in MSWM and MS-GM. (A) Representative immunoblots from homogenates of the
brain WM and GM areas of control and MS patients developed with antibodies
against the Lys-48 poly-ubiquitin. (B) The relative levels of Lys-48 ubiquitin were
calculated by dividing Lys-48 ubiquitin whole lane intensity on the immunoblots
by that of the corresponding coomassie blue stained lane. Each point represents
a patient and the horizontal bar is the average. *p<0.05. Other symbols are as in
Figure 4.1.
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Figure 4.3 - The amount of 20S proteasome α subunits is not diminished in MS.
(A) Representative immunoblots from homogenates of brain WM and GM areas
of control and MS patients developed with antibodies against the constitutive α
subunits of the 20S proteasome. (B) The relative levels of α subunits were
calculated by dividing α subunits band intensity on the western blot by that of the
corresponding coomassie blue stained lane. Each point represents a patient and
the horizontal bar is the average. *p<0.05. Other symbols are as in Figure 4.1.
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Figure 4.4 – Levels of 20S proteasome β1, β2 and β5 subunits are not
decreased in MS. Left three panels show representative immunoblots from
homogenates of brain WM and GM areas of control and MS patients developed
with antibodies against the β1 subunit (A), β2 subunit (B) and β5 subunit (C) of
the 20S proteasome. Right panels depict the corresponding levels of each of the
β subunits, which were calculated by dividing band intensity on the western blot
by that of the corresponding coomassie blue stained lane. Each point represents
a patient and the horizontal bar is the average. *p<0.05. Other symbols are as in
Figure 4.1.
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Figure 4.5 – Changes in the levels of the proteasomal regulators 11S and 19S in
MS. Left two panels show representative immunoblots from homogenates of
brain WM and GM areas of control and MS patients developed with antibodies
against the PA28α subunit of the 11S particle (A) and the Rpt4 subunit of the
19S particle (B). Right panels depict the corresponding levels of each of these
subunits, which were calculated by dividing bands intensity on the western blot
by those of the corresponding coomassie blue stained lane. Each point
represents a patient and the horizontal bar is the average. *p<0.05. Other
symbols are as in Figure 4.1.
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Figure 4.6 – Calpain activity and levels are increased in MS. Aliquots of the
cerebral homogenates from control and MS patients were used to determine the
soluble (active) (A) and total calpain activity (B) using a fluorescent peptide
substrate as described in “Materials and Methods”. Enzyme activity values are
expressed as fluorescence units (FU) / hour / µg protein. (C) Representative
immunoblots from homogenates of brain WM and GM areas of control and MS
patients developed with antibodies against µ-calpain. (D) The relative levels of µcalpain were calculated by dividing the band intensity on the western blot by that
of the corresponding coomassie blue stained lane. Each point represents a
patient and the horizontal bar is the average. *p<0.05, **p<0.01. Other symbols
are as in Figure 4.1.
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Figure 4.7 - Cathepsin B activity is increased in MS-WM and MS-GM. (A)
Aliquots of the cerebral homogenates from control and MS patients were used to
determine cathepsin B activity with a specific fluorescent peptide substrate at
acid pH as described in “Materials and Methods”. Enzyme activity values are
expressed as fluorescence units (FU) / hour / µg protein. (B) Representative
immunoblots from homogenates of brain WM and GM areas of control and MS
patients developed with an antibody cathepsin B. (C) The relative levels of 31kDa
form of cathepsin B were calculated by dividing the band intensity on the western
blot by that of the corresponding coomassie blue stained lane. Each point
represents a patient and the horizontal bar is the average. *p<0.05. Other
symbols are as in Figure 4.1.
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Figure 4.8 – Levels of the mitochondrial LON protease are unchanged in MS. (A)
Representative immunoblots from homogenates of brain WM and GM areas of
control and MS patients developed with an antibody against LONp1. (B) The
relative levels of Lon protease were calculated by dividing the band intensity on
the western blot by that of the corresponding coomassie blue stained lane. Each
point represents a patient and the horizontal bar is the average. Other symbols
are as in Figure 4.1.
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5 General Discussion
5.1 Major Conclusions
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the
human

CNS

(Trapp

and

Syts,

2009)

and

experimental

autoimmune

encephalomyelitis (EAE) is a classical animal model recapitulating a number of
clinical and pathological features of MS (Gold et al., 2000). A substantial amount
of data has shown that oxidative stress plays a major role in the pathogenesis of
both MS and EAE. One of the most significant consequences of severe oxidative
stress is protein carbonylation (Bizzozero, 2009). This laboratory has recently
shown that protein carbonyls accumulate in the brain of MS patients (Bizzozero
et al., 2005) and in the spinal cord of rats with acute EAE (Smerjac and
Bizzozero, 2008). However, our knowledge of protein carbonylation in
inflammatory demyelinating disorders is still limited. The objectives of this thesis
were (1) to identify the target cells and oxidized proteins in the cerebellum of
EAE animals, and (2) to uncover the mechanism(s) underlying the accumulation
of carbonylated proteins in the chronic phase of EAE and in MS patients.
First, I characterized the occurrence of protein carbonylation in the acute
(inflammatory) and the chronic (neurodegenerative) phase of EAE. Double
immunofluorescence microscopy of affected cerebella showed that most of the
carbonyl staining is occurring in white matter astrocytes, and to a lesser extent in
microglia/macrophages, both in the acute and chronic phase. By 2D-oxyblot and
mass spectrometry, β-actin, β-tubulin, GFAP and HSC-71 were identified as the
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major targets of carbonylation throughout the disease (Chapter 2). An increase in
the proportion of carbonylated cytoskeletal proteins was then observed in
cerebellar astrocytes during the chronic phase of EAE (Table 5.1). Astrocytes are
very important in MS and EAE since they aid in degeneration and demyelination,
by promoting inflammation, damage of oligodendrocytes and axons, and glial
scarring.
Second, I explored the mechanism(s) underlying the accumulation of
protein carbonyls in chronic EAE. Since the amount of protein carbonyls is
determined by the rate of generation and degradation and since there is less
oxidative stress in the chronic relative to the acute phase of EAE (Table 5.1), I
proposed that the accumulation of carbonylated cytoskeletal proteins in chronic
EAE might be due to a decline in their catabolism. This could be caused either by
a defective proteolytic system or by reduced susceptibility of carbonylated
proteins to degradation. This hypothesis was tested by identifying the proteolytic
system responsible for removal of carbonylated proteins in LPS-stimulated
astrocytes. The results clearly showed that only the proteasome inhibitor
epoxomicin causes a build-up of carbonylated proteins. More importantly, we
discovered that the proteasomal chymotryptic-like activity, which is responsible
for the removal of oxidized proteins, is impaired in the cerebellum of mice with
chronic EAE while the activities of the other two proteolytic systems (calpain and
lysosomal cathepsin B) remain the same or are increased. Furthermore,
experiments in a cell-free system showed that carbonylated cytoskeletal proteins
from acute and chronic EAE are equally susceptible to proteasomal degradation.
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Altogether, these data indicate that diminished proteasomal activity may
contribute the accumulation of carbonylated cytoskeletal proteins in chronic EAE
(see Chapter 3).

Table 5.1 Summary of protein carbonyl levels in acute and chronic EAE
Acute

Chronic

Yes: ↓GSH

Yes: ↓ GSH

(~60% of control)

(~83% of control)

Carbonylated GFAP/total GFAP

No change

↑(4-5 folds)

Carbonylated β-Actin/total β-actin

No change

↑(2-3 folds)

Carbonylated β-Tubulin/total β-Tubulin

No change

↑(1-2 folds)

Oxidative stress

Third, based on the finding of reduced proteasomal activities in chronic
EAE, I asked whether the function of the 20S proteasome is also impaired in MS.
To this end, I measured the various proteasomal activities and the capacity to
digest ubiquitinylated proteins in 13 control and 13 MS brains. Similar to what we
found in chronic EAE, the three peptidolytic activities of 20S proteasome are
reduced in the white matter and gray matter of MS patients. Accumulation of
proteins containing Lys-48 polyubiquitin also demonstrates failure of the 26S
proteasome. In addition, I assessed the content of the alpha, the three beta
(catalytic) subunits and the two major activators (19S and PA28) in MS patients.
Interestingly, the amount of proteasome and that of the catalytic subunits are not
lessened in MS, suggesting inactivation of 20S proteasome. While the amount of
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19S is decreased only in MS white matter, the content of PA28 is reduced in both
white matter and gray matter of MS. Moreover, under the conditions of the cellfree assay used in this study, the 19S and PA28 caps are unlikely to be attached
to the 20S core particle (Rivett, 2002). Therefore, the reduced level of these
activators is not likely responsible for the impairment of proteasomal activity. The
possible mechanisms underlying the diminished proteasomal function will be
discussed later in this chapter.
The findings presented in this thesis are important not only for
understanding why PCOs accumulate in the CNS of EAE animals and MS
patients, but also for gaining better insights into the pathophysiology of these
disorders. In addition, my findings provide the basis for exploring the
mechanisms underlying proteasomal impairment in inflammatory demyelinating
disorders. It is tempting to speculate that activating the proteasome or preventing
proteasomal dysfunction might be of benefit for MS patients.

5.2 The proteasome may play an important role in the pathophysiology of
EAE/MS.
The role of the proteasome system in the pathophysiology of EAE/MS is
not completely understood. The 20S proteasome is responsible for the
degradation of oxidized protein while the ubiquitin proteasome system is involved
in the degradation of cellular proteins including many signal molecules
(Shringarpure et al., 2003) and myelin/axonal proteins (Ehlers, 2004; Korhonen
and Lindholm, 2004). Therefore, proteasome impairment is likely to cause the
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accumulation of oxidized/misfolded proteins and proapoptotic factors that could
lead to a series of deleterious events including apoptosis.
Findings in cell systems and in several animal models have demonstrated
that disturbances of proteasome activity cause oligodendrocyte/neuron death,
neurodegeneration and axonal damage, which interestingly are the major
histopathological feaures of chronic MS/EAE (Kurnellas et al., 2007). For
example, proteasome inhibition induces mitochondrial and endoplasmic reticulum
dysfunction and apoptotic cell death in cultured obligodendrocytes and neurons
(Ustundag et al., 2007; Goldbaum et al., 2006). In addition, inhibition of
proteasome activity may play a causal role in mediating the neuropathology in
Alzheimer's disease (Ding, 2003). Also, the accumulation of ubiquitinated
proteins resulting from proteasome inhibition in neuronal cells were shown to
trigger a proinflammatory response characterized by upregulation of COX-2 and
production

of

prostaglandin

PGE2,

which

in

turn

contributes

to

neurodegeneration (Rockwell et al., 2000). Furthermore, it has been shown that
both protein trafficking and neuronal connectivity become dysfunctional by
protein aggregates. This is caused by decreased proteasomal activity in the
neuronal cell body which specifically triggers increased proteosomal activity in
the axon, leading to its damage (Korhonen and Lindholm, 2004). Finally,
proteasome activity is required for activation of NFkB (Hershko and Ciechanover,
1992), a transcription factor with neuroprotective properties in vitro and in vivo
(Mattson and Furukawa, 1998). Therefore, a fully functional proteasome (both
20S and 26S) may play an important role as a protective barrier, preventing
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sudden elevations in oxidative damage, preserving cellular homeostasis, and
preventing the activation of apoptotic cascades (Ding, 2006).

In acute EAE, where extensive inflammation leads to severe oxidative
stress, cells have normal or even increased proteasomal activity. Because of this
elevated degradation capacity, the amount of carbonylated cytoskeletal proteins
including β-actin, β-tubulin and GFAP were unaltered. The augmented
proteasomal activity is most likely the result of proteasome plasticity and/or the
overexpression of heat shock proteins. Proteasome plasticity means that the
expression and composition of individual 20S subunits can be altered in
response to environmental and genetic stimuli (James et al., 2006). For example,
proteasome expression in neural cells is dramatically altered in response to
oxidative stress while inflammatory stimuli could alter both proteasome
expression and proteasome composition (from constitutive proteasome to
immuno-proteasome) (Keller et al., 2002).

As one transitions from the acute to the chronic phase and once the
amount of oxidized substrates reaches a point where proteasome can no longer
digest them, cells lose the homeostasis. In this situation, the capacity of the
proteasome to protect against stress may become compromised as well.
Moreover, a rise in oxidative stress and activation of apoptotic pathways likely
cause a feed-forward cycle that results in additional proteasome inhibition,
greater accumulation of damaged proteins and further activation of death
cascades (Ding, 2006). Therefore, proteasome inhibition in the chronic disease
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may be a trigger for initiation of these deleterious events. In other words, the time
required for the onset of neuropathology and neurodegeneration may depend on
how much the proteasome can preserve its function. After that, loss of
proteasome function will lead to the development of neurodegeneration.

It is well known that binding of PA28 with the 20S core containing the
inducible β subunits aids in the generation of immunogenic peptides (Kloetzel,
2001). Thus, the lower amount of PA28 in MS may have a negative impact on
immune function as well. However, it is also possible that the lower content of
regulatory proteins in MS may be an adaptive response to the increased demand
for degrading oxidized proteins. As suggested by Ferrington (2005), low levels of
regulatory proteins guarantees that a population of 20S remains free and
available to degrade oxidized proteins (Ferrington et al., 2005).

In the future, we will need to answer several questions. In this study we
have shown that there is an increase of chymotrypsin-like proteasome activity in
acute EAE, pathologically characterized by inflammation, and a decline in chronic
EAE, pathologically characterized by demyelination. Knowing when during the
course of EAE the proteasomal activity becomes compromised will be important
(1) for understanding the role of proteasome demise in this disease, and (2) for
identifying the time point for future pharmacological intervention directed towards
activating the proteasome. Furthermore, since the goal of this study was to
explore the mechanism underlying the accumulation of carbonylated cytoskeletal
proteins within cerebellar astrocytes in chronic EAE, I measured the
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accumulation of poly-ubiquitinated proteins only in these cells. However,
exposure to environmental stressors (e.g., free radicals) and protective
mechanisms (e.g., heat shock proteins, antioxidants) that are unique to each cell
type can influence the extent and specificity of the effect (Kapphahn et al., 2007).
Therefore, it will be important to know whether proteasome impairment is
happening in other cell types, particularly in neurons and oligodendrocytes. It is
quite

possible

that

as

disease

progresses

damaged

neurons

and

oligodendrocytes die and are removed from the tissue by autophagy; leaving
behind astrocytes loaded with undigested proteins. Moreover, my study did not
investigate proteasomes in different cellular compartments. As a result, possible
disease-associated changes in subcellular localization of this particle were not
detected. Altering the subcellular content of proteasomes could impact on
specific functions, such as cell cycle regulation, control of signal transduction and
gene expression, the degradation of oxidized/misfolded proteins, and antigen
presentation and DNA repair (Martinez-Vicente et al., 2005). In addition, studies
have reported that the 26S proteasome may be more vulnerable to inactivation
as compared to the 20S proteasome (Das et al., 2005), raising the possibility that
26S proteasome function may be compromised prior to the 20S proteasome in
neurodegenerative disorders.
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5.3 Future directions
5.3.1 Carbonylation may affect the major properties of cytoskeletal proteins like
GFAP.
As discussed in Chapter 2, the amount of oxidized cytoskeletal proteins
including β-actin, β-tubulin and GFAP in cerebellum were elevated in chronic
EAE. Since protein carbonylation is known to affect cytoskeleton stability, it is fair
to suggest that the observed changes have physiological consequences. As
mentioned before, carbonylation of tubulin leads to disassembly and instability
microtubules, and actin filament are easily depolymerized upon carbonylation
(Banan et al., 2001). Yet, the effect of carbonylation on GFAP solubility, stability
and polymerization has never been investigated. I therefore studied if GFAP
oxidation may affect its properties. To this end, I prepared carbonylated GFAP by
culturing astrocytes in the presence of the glutathione depletor DEM and then
tested the solubility of oxidized GFAP at various concentrations of salt. This
technique has been used to evaluate the stability of intermediate-filamentassociated protein interactions (Hsiao et al., 2005). As shown in Appendix B, the
proportion of carbonylated GFAP in cultured astrocytes was significantly elevated
after incubation with DEM. The cell lysates from control and DEM-treated
astrocytes were then incubated with increasing concentrations of potassium
chloride, starting at 150mM which is close to the ionic strength in physiological
medium. Interestingly, after 2 hours of incubation with 150mM KCl, the ratio of
GFAP monomer to polymer is greatly elevated in the cell lysates from DEMtreated astrocytes relative to the control (Figure 5.1). These data indicate that
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DEM-induced oxidation decreased the stability of GFAP under physiological ionic
strength. Higher concentration of KCl (500mM and 1M) dissembles most of
GFAP polymers into monomers even in the control cells (Figure 5.1). Similar
pattern was observed for β-actin and β-tubulin (see appendix C).

While these results are exciting and they seem to support the stated
hypothesis, more detailed studies are needed before we can definitively conclude
that carbonylation decreases the stability of GFAP. Particularly, because the
monomer-polymer equilibrium is affected by a number of additional factors
(William et al., 1987). Further studies on GFAP properties in cell-free system
upon direct carbonylation should be performed to clarify the relationship of
carbonylation and GFAP properties.
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Figure 5.1 The solubility of GFAP in DEM-treated astrocytes augmented upon
incubation of KCl. The cell homogenates from control and DEM treated
astrocytes were incubated with different concentration of KCl in the presence of
0.5% v/v Triton X-100. After 2 hours, supernatant (monomer, M) and pellet
(polymer, P) were separated by 16,000 g of centrifugation. The same volume of
supernatant and pellet was loaded and probed with antibodies against GFAP.
Densitometric scans were obtained to calculate the ratio of monomer to polymer
in GFAP under various conditions (Panel B). Panel A is the representative blot.
The data from the condition of 150mM KCl are based on the film with the shorter
exposure time, shown in the upper row. Values represent the mean ± SEM of 3
experiments. *p<0.05.
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5.3.2 Possible mechanisms underlying proteasome impairment in chronic EAE
and MS.
Decreased

proteasomal

activity

has

been

reported

in

several

neurodegenerative disorders including Alzheimer’s disease, Parkinson disease,
amyotrophic lateral sclerosis, and Huntington’s disease (Ciechanover and
Brundin, 2003). Thus, a loss of proteasome function may be a general
phenomenon of neurodegenerative disorders. A missing aspect from all of these
studies is a mechanistic understanding of the cause(s) for diminished
proteasome function.
One potential explanation for the reduced proteasome function in EAE/MS
might be a decreased expression of the catalytic core particle. However, based
on the quantification of the 20S proteasome α and β subunits in MS by western
blot, I concluded that changes in proteasome unit numbers may not explain the
observed decrease in proteasome activity. Therefore, I proposed several
mechanisms underlying proteasomal impairment in MS/EAE: (1) inadequate
content of endogenous proteasomal activators, (2) enhanced concentration of
endogenous proteasomal inhibitors, (3) increased immunoproteasome levels, (4)
impaired proteasomal assembly, (5) post-translational modification including
phosphorylation and oxidative damage, and (6) changes in proteasomal stability
and structural conformation (Figure 5.2).
The best known activator of 20S proteasome is PA700 (19S), which
stimulates the degradation of protein substrates in an ATP- and ubiquitindependent manner. Two other activators, PA28 (11S) and PA200, do not
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recognize ubiquitinated proteins or use ATP (Rechsteiner and Hill, 2005). PA200
is nuclear and involved in DNA repair. The role of this protein on activating
proteasome is still controversial since it is also reported that yeast protein Blm3p,
homologous to mammalian PA200, does not stimulate proteasome activity in
vitro (Fehlker et al., 2003). While reduced PA700 levels are observed in white
matter of MS relative to the control, it is also possible that PA 700 may contain
defects (e.g. oxidative modifications) that prevent its binding to and activation of
the 20S particle. Thus, it is likely that decreased assembly of the 26S
proteasome could result in delayed degradation of ubuquitin-conjugated proteins.
With regard to the other cap, it is well known that PA28 in the cytoplasm forms a
hybrid proteasome that functions in class I antigen presentation (see Chapter 1).
However, in the absence of inflammation, elevated levels of PA28 may generate
more hybrid proteasomes, thereby enhancing the total proteolytic activity
(Tanahashi et al., 2000). A possible mechanism underlying proteasomal
activation by 11S is that the activator binding induces opening of the entrance
and exit gate of the proteasome and that a central channel formed through the
center of the activator aligns with the open entrance gate of the proteasome. As
a consequence, peptide substrates can easily diffuse through the central channel
of the activator and into the proteasomal interior (Rechsteiner and Hill, 2005). I
found a low 11S expression in MS patients relative to the control, suggesting that
down-regulation of this cap might partially contribute to proteasomal impairment.
However, under the assay conditions employed herein, the 11S or 19S
complexes are likely to be detached from the 20S particle. Hence, additional
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mechanisms are probably responsible for the loss of proteasomal function in
EAE and MS.
Several proteins including hsp90, PI31, and PR39 have been identified as
negative regulators of proteasomal activity. The chaperone protein hsp90 inhibits
hydrolysis of fluorogenic peptides by the 20S proteasome approximately two-fold
and the inhibition is abrogated by low levels of PA28 (Lu et al., 2001). Two other
proline-rich proteins, PI31 and PR39, inhibit the chymotrypsin-like and caspaselike active sites of the proteasome more than the trypsin-like site (Zaiss et al.,
1999), which interestingly is a pattern of inhibition similar to what I found in
chronic EAE. PI31 is a competitive inhibitor of PA28 activation while PR39 is a
noncompetitive reversible inhibitor of all proteasome complexes (Rechsteiner
and Hill, 2005). It has been suggested that PR39 binds to the α7 subunit,
preventing proteasome complexes from switching between open and closed
conformations (Gaczynska et al., 2003). PI31 has been shown to have a 50-fold
higher affinity for the 20S proteasome than that of PA28; however, inhibition of
proteasome complexes is less than 50%, even at extremely high levels of PI31
(McCutchen-Maloney et al., 2000). Consequently, the decrease of >50% in
proteasomal activities that I measured in the MS specimens cannot be accounted
by an increase in PI31.

Furthermore, I have obtained preliminary data

suggesting that amount of PI31 is actually decreased in MS. The role of other
proteasome inhibitors such as 4-HNE cross-linked proteins (Friguet et al., 2006)
and lipofuscin/ceroid fluorescent pigments (Sitte et al., 2000), will also need to be
investigated in these disorders.
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Under conditions of acute immune or stress response, 20S proteasome
core subunits β1, β2, β5 are substituted by the interferon-γ inducible subunits β1i,
β2i, β5i. The resulting immuno-proteasome has lower chymotrypsin-like and
caspase-like activities than the regular 20S subunit (Ferrington et al., 2005).
Therefore, an elevation in immuno-proteasome levels could be another possibility
for the decreased hydrolysis of fluorogenic peptides in MS tissue.

In fact,

inflammatory cytokine TNF-α and nitric oxide (NO) have been detected in several
inflammatory diseases including MS (Farias et al., 2007), and cultured cells
respond to TNF-α and NO by up-regulating expression of the inducible β
subunits (Husom et al., 2004).
The present studies did not allow me to determine if the diminished
peptidolytic activity in EAE/MS is due to failure of the various subunits to
assemble into a functional complex. However, in the case of EAE this is unlikely,
since peptide hydrolysis occurs only within the functional catalytic core (i.e. free
subunits are inactive) (Kapphahn, 2007) and the trypsin-like activity is not altered.
At this time, I cannot rule out the possibility of impaired proteasomal assembly in
MS since all of the three peptidolytic activities are reduced to a similar extent.
Proteasomal assembly involves the following two events: (a) organization of αsubunits in seven-member rings under the supervision and assistance of
proteasome assembling chaperones 1, 2 and 3 (PAC1-3), and (b) association of
precursor β-subunits with UMP1/POMP accessory protein that in conjunction to
the α-subunits rings gives rise to 20S proteasomes (Chondrogianni and Gonos,
2008). In addition, proteasomal ATPase-associated factor 1 (PAAF1) that
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interacts with proteasomal ATPases, has been shown to act as negative
regulator of the proteasome activities by affecting the assembly/disassembly of
the 26S complex (Chondrogianni and Gonos, 2008). It is clear that more studies
on the assembly/disassembly of 20S proteasome, 26S complex, PA28-20S
complex and hybrid proteasome need to be performed in the future.
Some post-translational modifications of the 20S subunits have been
identified

that

affect

proteasome

activities

(Fig.

5.2;

Post-translational

modifications). Specific subunits of the 20S proteasome are targeted for
modification by the lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) and
the modified proteasomes exhibit a decline in peptidase activities (Reinheckel et
al., 2000; Bulteau et al., 2001; Farout, 2006). In addition to lipid peroxidation,
proteasome activity can be impaired by the glycoxidation product glyoxal
(Bulteau et al., 2001b), γ-ketoaldehydes (isoketals) (Davies et al., 2002), direct
carbonylation (Kessova and Cederbaum, 2005), nitric oxide and nitrosylated
glutathione (Glockzin et al., 1999), which are all increased during oxidative stress
(Keller et al., 1998).
In addition, the serum and CSF of patients with multiple sclerosis contain
autoantibodies against the proteasome (Mayo et al., 2002). Therefore, it is
possible that the reaction of autoantibodies and proteasome antigen could
reduce its activity.
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Figure 5.2 Possible mechanisms underlying proteasomal impairment. In
conclusion, the understanding of proteasomal impairment in MS/EAE is a major
but worthwhile undertaking. Since the proteasome is considered to be a
therapeutic target, the knowledge of the precise molecular mechanisms
underlying the alteration of proteasome functions will help to design more specific
and probably more effective compounds that modulate its activity.
5.4 Scientific Impact
This is the first study showing an initial increase and then decline in the
proteasomal peptidolytic activities during the course of EAE. The proteasomal
impairment is also observed in MS patients. While the current studies raise a
number of questions, the finding that proteasome are inhibited in chronic
EAE/MS will aid our understanding of the pathophysiology of EAE/MS, and may
provide the foundation for future studies aimed at developing new approaches to
treat MS.
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Abstract
We have investigated the effect of reactive carbonyl species (RCS)-trapping
agents on the formation of protein carbonyls during depletion of brain glutathione
(GSH). To this end, rat brain slices were incubated with the GSH-depletor diethyl
maleate in the absence or presence of chemically different RCS scavengers
(hydralazine, methoxylamine, aminoguanidine, pyridoxamine, carnosine, taurine
and z-histidine hydrazide). Despite their strong reactivity towards the most
common RCS, none of the scavengers tested, with the exception of hydralazine,
prevented protein carbonylation.

These findings suggest that the majority of

protein-associated carbonyl groups in this oxidative stress paradigm do not
derive from stable lipid peroxidation products like malondialdehyde (MDA),
acrolein and 4-hydroxynonenal (4-HNE). This conclusion was confirmed by the
observation that the amount of MDA-, acrolein- and 4-HNE-protein adducts does
not increase upon GSH depletion. Additional studies revealed that the efficacy of
hydralazine at preventing carbonylation was due to its ability to reduce oxidative
stress, most likely by inhibiting mitochondrial production of superoxide and/or by
scavenging lipid free radicals.
Introduction
Carbonylation

constitutes

the

major

and

most

common

oxidative

modification of proteins [1]. Protein carbonyls (PCOs) have been shown to affect
the function and/or metabolic stability of the modified proteins [2], and thus they
are likely to play an important role in the pathophysiology of disorders with
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considerable oxidative stress. Carbonylation of brain proteins has been
implicated in the etiology and/or progression of several neurodegenerative
disorders including Alzheimer’s disease [3], Parkinson’s disease [4], amyotrophic
lateral sclerosis [5] and multiple sclerosis [6].
Carbonyl groups are introduced into proteins by two distinct mechanisms:
oxidative (direct) and non-oxidative (indirect). Oxidative mechanisms, which are
metal ion-catalyzed, involve the direct reaction of certain reactive oxygen species
(e.g. hydrogen peroxide, lipid hydroperoxides, etc) with protein side-chains.
Common amino acid targets of direct oxidative processes leading to
carbonylation are Thr, Lys, Arg, and Pro. Threonine side-chains are oxidized to
a-amino-b-ketobutyric acid while oxidative deamination of Lys, Arg and Pro
generates a-aminoadipic semialdehyde and glutamic semialdehyde [7]. Nonoxidative carbonylation of proteins involves the reaction of the nucleophilic
centers in Cys, His or Lys residues with reactive carbonyl species (RCS). RCS
are carbonyl-containing molecules derived from the oxidation of lipids (e.g. 4hydroxynonenal (4-HNE), malondialdehyde (MDA), acrolein) and carbohydrates
(e.g. glyoxal, methylglyoxal) [7].
To understand the process underlying the formation and accumulation of
PCOs during oxidative stress, we recently utilized a brain slices system where
carbonyls are induced by acute depletion of cellular glutathione (GSH) with
diethyl maleate (DEM) or with 1,2-bis(2-chloroethyl)-1-nitrosourea [8]. We found
that under these conditions there is an increased mitochondrial production of
reactive oxygen species (ROS), which leads to extensive lipid peroxidation (LPO)
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and protein carbonylation by a metal ion-catalyzed process likely involving the
formation of hydroxyl radical. More recently we demonstrated that LPO is
required for the carbonylation of cytoskeletal and membrane proteins [9].
Furthermore, evidence was presented suggesting that the mechanism underlying
LPO-mediated protein carbonylation is the direct oxidation of amino acid sidechains by lipid hydroperoxides (or their immediate decomposition products lipid
peroxyl and lipid alkoxyl radicals) rather than the attachment of RCS like 4-HNE
and MDA.
The present study was designed to determine if carbonylation of brain
proteins that takes place during acute GSH depletion indeed occurs by an
oxidative mechanism. To achieve this objective we have (1) investigated the
possible presence of protein-bound lipid aldehydes using antibodies against
MDA, 4-HNE and acrolein, and (2) tested the efficacy of several RCS-trapping
agents (hydralazine, methoxylamine, aminoguanidine, pyridoxamine, carnosine,
taurine and histidine hydrazide) at preventing protein carbonylation in rat brain
slices incubated with DEM. The results show that GSH depletion does not
generate protein carbonyls by the indirect (non-oxidative) mechanism. This was
confirmed by the finding that none of the RCS scavengers tested, with the
exception of hydralazine, prevented protein carbonylation. Additional studies
revealed that the efficacy of hydralazine is mostly due to its antioxidant properties.
A preliminary account of these results has been presented in abstract form [10].
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Materials and Methods
Chemicals
Aminoguanidine,

apocynin,

L-carnosine,

clorgyline,

deprenyl,

DEM,

hydralazine, hydroxylamine, methoxylamine and taurine were purchased from
Sigma-Aldrich (St. Louis, MO). Pyridoxamine was from Fluka (Ronkonkoma, NY).
z-Histidine hydrazide was from Peninsula Laboratories (San Carlos, CA). 15Hydroperoxy-5,8,11,13-eicoanotetraenoic acid (15-HpETE) was obtained from
Cayman Chemicals (Ann Arbor, MI). Anti-4-HNE (AB46544), anti-MDA (AB27642)
and anti-acrolein (AB37110) rabbit polyclonal antibodies were from Abcam
(Cambridge, MA). All other reagents were of the highest purity available.
Incubation of rat brain slices
Forty-day old Sprague-Dawley male rats were used throughout. Housing
and handling of the animals as well as the euthanasia procedure were in strict
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and
were approved by the Institutional Animal Care and Use Committee. Animals
were killed by decapitation, and the brains were rapidly removed and sliced in
two directions at right angle in sections 400µm-thick using surgical grade, carbon
steel razor blades. Slices corresponding to ~80 mg of tissue were transferred to
flasks containing 3 ml of Hank’s balanced salt solution supplemented with 10 mM
D-glucose, and were incubated at 37˚C under 95% O2/5% CO2. Drugs were
added at the beginning of the incubation period as indicated in the figure legends.
After 2h, aliquots were taken from the supernatant for H2O2 determination using
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the Fe/xylenol orange (FOX) assay [11]. Tissue sections were then collected by
low-speed centrifugation and rinsed twice with 2 ml of ice-cold saline solution.
Slices were homogenized by sonication in PEN buffer (10 mM sodium phosphate
pH 7.0, 1 mM EDTA and 0.1 mM neocuproine) containing 1mM 4,5-dihydroxy1,3-benzene sulfonate and 0.5mM dithiothreitol to prevent further protein
oxidation. Homogenates were kept at -20˚C until use. Protein concentration was
assessed with the Bio-Rad DCT protein assay using bovine serum albumin (BSA)
as standard.
Determination of non-protein thiols (NPSHs)
NPSHs, which are made mostly of GSH and small amounts of cysteine and
homocysteine, were determined spectrophotometrically with 5,5’-dithiobis(2nitrobenzoic) acid [12].
Measurement of lipid peroxidation
Lipid peroxidation was assessed by measuring the amount of thiobarbituric
acid reactive substances (TBARS) in the tissue homogenates as described
previously [13].
Measurement of protein carbonylation by western blotting
Protein carbonyl groups were measured by western blot analysis using the
OxyBlot™ protein oxidation detection kit (Intergen Co., Purchase, NY) as we
described earlier [9]. In brief, proteins (5 µg) were incubated with 2,4dinitrophenyl-hydrazine

to

form

the
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2,4-dinitrophenyl

(DNP)

hydrazone

derivatives. Proteins were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and blotted to polyvinylidene difluoride (PVDF)
membranes. DNP-containing proteins were then immunostained using rabbit
anti-DNP antiserum (1:500) and goat anti-rabbit IgG conjugated to horseradish
peroxidase

(HRP)

(1:2000).

Blots

were

developed

by

enhanced

chemioluminescence (ECL) using the Western Lightning ECL™ kit from PerkinElmer (Boston, MA). The developed films were scanned in a Hewlett Packard
Scanjet 4890 and the images quantified using the NIH image analysis program
version 1.63.
Reaction of oxidized brain proteins with carbonyl scavengers
Proteins from DEM-treated brain slices were precipitated with 1%
sulfosalicylic acid and suspended 20mM sodium phosphate buffer pH 7.5
containing 2mM EDTA. Aliquots (50µg of protein) were incubated at 20˚C in the
absence or presence of various carbonyl scavengers. After 2h, proteins were
derivatized with DNPH and analyzed by western blotting as described above.
Assessment of MDA-, 4-HNE- and acrolein-protein adducts by western blotting
Proteins from control and GSH-depleted brain slices were separated by
SDS-PAGE and blotted against PVDF membranes. RCS-protein adducts were
detected using polyclonal rabbit antibodies against MDA (1:1000), 4-HNE
(1:1000) and acrolein (1:2000) and HRP-conjugated goat anti-rabbit IgG (1:2000).
Blots were developed by ECL as described above.
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Additional assays
The effect of hydralazine (50µM-50mM) on the rate of pyrogallol autoxidation
was carried out as described by Semsei et al., [14]. The effectiveness of RCSscavengers at removing MDA was assessed by titrating the unreacted
dialdehyde with thiobarbituric acid [13]. The efficacy of RCS-trapping drugs at
scavenging 4-HNE was measured by titrating the unreacted unsaturated alkenal
with N-methyl-2-phenylindole in the presence methanesulfonic acid [6]. The
ability of RCS-trapping agents at scavenging acrolein was determined with
treating unreacted acrolein with cysteine ethyl ester and then titrating the excess
thiols with 5,5’-dithiobis(2-nitrobenzoic) acid.
Statistical Analysis
Results were analyzed for statistical significance with Student's unpaired t
test utilizing the GraphPad Prism® (version 4) program (GraphPad Software Inc.,
San Diego, CA).
Results
DEM-induced protein carbonylation in brain slices
DEM is an α,β-unsaturated dicarboxylic acid that conjugates to GSH via a
reaction catalyzed by glutathione-S-transferase [15]. Incubation of brain slices
with 10mM DEM for 2 h diminishes NPSHs by 85% and increased TBARS and
PCO levels by 70% and 100%, respectively [8]. As described in our previous
study [9], the majority of the carbonylated proteins from both control and DEM133

treated slices have molecular weights between 40K and 120K. Among these
species are the major cytoskeleton proteins including α/β-tubulin, β-actin, the
neuronal intermediate filament proteins and glial fibrillary acidic protein.
Effect of carbonyl scavengers on DEM-induced protein carbonylation in brain
slices
The detailed chemical structure of the carbonyl trapping agents used in this
study is shown in Fig. A.1. These agents include three hydrazines (hydralazine
[16], aminoguanidine [17] and z-histidine hydrazide [18]) and four primary amines
(methoxylamine [19], pyridoxamine [20], carnosine [21] and taurine [22]). We
chose several, chemically different RCS scavengers because their reactivity
toward various RCS differs considerably [23]. In cell-free systems we found that
only the three hydrazines, and to a lesser extent carnosine, effectively trap MDA
(Fig.A.2A), while all the scavengers showed high reactivity towards 4-HNE (Fig.
2B). Except for aminoguanidine, most drugs also adducted the highly reactive
acrolein (Fig. A.2C). It is important to note that these scavengers were also able
to prevent the formation protein-RCS adducts in tissue slices incubated with
MDA or 4-HNE, indicating that they are cell-permeable (data not shown). We
then tested the ability of these RCS scavengers to prevent the appearance of
protein carbonyls in brain sections incubated with DEM. As shown in Fig. A.3,
none of the carbonyl scavengers prevented DEM-induced glutathione depletion
and, among the seven drugs tested, only hydralazine (50µ-500µM) inhibited the
formation of protein carbonyls. Aminoguanidine shows an effect only at
concentrations ≥ 1 mM [9]. The observation that just hydralazine prevents PCO
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formation was surprising, and suggests that either protein carbonylation takes
place through an indirect mechanism and that only hydralazine effectively traps
RCS in intact cells, or that the efficacy of this drug is due to some property that is
unrelated to RCS adduction.
To distinguish between the above possibilities, we determined by western
blot analysis whether or not RCS-protein adducts are formed in GSH-depleted
brain slices. As depicted in Fig. A.4, antibodies against MDA, acrolein and 4-HNE
labeled a number of distinct bands, and the intensity of neither the whole lane not
the individual modified proteins was changed in DEM-treated sections. This
indicates that MDA-protein, ACR-protein and 4-HNE-protein adducts are not
formed to any appreciable degree in this model of oxidative stress and that the
effect of hydralazine on protein carbonylation is not due to its ability to remove
RCS.
The possibility that hydralazine reacts directly with protein carbonyls was
examined by incubating carbonylated proteins derived from DEM-treated brain
slices with hydralazine (0.1-1mM). Only 1mM hydralazine efficiently reduced the
amount of protein bound carbonyls, suggesting that the effectiveness of 50µM
hydralazine at preventing protein carbonylation in intact cells is unlikely caused
by a direct reaction between the drug and protein-bound carbonyl groups (Fig.
A.5A). Interestingly, 100µM hydralazine was found to partially inhibit the 15HpETE-induced oxidation of proteins (Fig. A.5B), and this could be due to
scavenging of alkoxyl and peroxyl radicals produced during the metal ioncatalyzed decomposition of the lipid hydroperoxide and/or to the sequestration of
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iron and copper ions. In any case, the concentration of hydralazine needed to
cause this effect in a cell-free system is still higher than that required to suppress
PCO formation in GSH-depleted brain sections (see below).
Antioxidant properties of hydralazine
Because hydralazine is known to have antioxidant properties in several
oxidative stress settings [24] and based on the observation that it also lowers the
levels of TBARS in GSH-depleted brain sections (data not shown), we
hypothesized that this drug may just be reducing oxidative stress and indirectly
carbonyl formation. To address this issue, we determined hydrogen peroxide and
PCO levels in DEM-treated brain slices incubated with different concentrations of
hydralazine. As shown in Fig. A.6, both H2O2 levels and the amount of protein
carbonyls diminished with increasing concentrations of hydralazine (0.5-500µM),
indicating that the inhibitor is acting mostly as an antioxidant.
A series of additional studies were conducted to ascertain the mechanism
underlying the antioxidant properties of hydralazine. We first investigated the
possibility that hydralazine could be scavenging peroxides (H2O2, lipid
hydroperoxides) or superoxide radicals. Fig. A.7A shows that hydralazine does
not react with either H2O2 or 15-HpETE even at high concentrations (0.5mM).
The ability of hydralazine to scavenge superoxide was tested with pyrogallol. In
the pyrogallol system, superoxide radicals are formed from molecular oxygen
and the detecting system is the pyrogallol itself. Hydralazine reduced superoxide
levels only at a concentration ≥ 5mM, which is 1000-times higher than that
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required to abolish H2O2 production (Fig. A.7B). Thus, the most likely mechanism
underlying the antioxidant effects of hydralazine is the inhibition of processes
responsible of ROS production.
In a previous study we showed that most of the superoxide generated
during GSH depletion comes from mitochondria (inhibited by carbonyl cyanide 3chlorophenylhydrazone) and to a lesser extent from cytochrome P-450 (inhibited
with proadifen), but not from xanthine oxidase (unaltered by oxypurinol) [8].
However, other possible sources of superoxide that are targeted by hydralazine,
like NADPH oxidase (24) and monoamine oxidase (MAO) [25], were not
investigated in that study. To address this issue, brain slices were incubated with
DEM in the presence or absence of apocynin (NADPH oxidase inhibitor [26]),
clorgyline

(MAO-A

inhibitor,

[25]),

deprenyl

(MAO-B

inhibitor

[25])

or

hydroxylamine (MAO-A/B inhibitor [27]). As shown in Fig. A.8, protein
carbonylation was not decreased by any of these drugs, indicating that these
enzymes are not involved in the generation of superoxide during GSH depletion.
In sum, the above results are in agreement with previous findings suggesting that
hydralazine reduces superoxide production from mitochondria [28, 29]. At this
time, however, we cannot rule out the possibility that hydralazine acts also by
scavenging of lipid alkoxyl and peroxyl radicals, mainly because the
concentration of these radicals and hydralazine in the cell membranes may be
quite different than those used in our cell-free experiment (Fig. A.5B).
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Discussion
In this study, we present evidence that RCS-trapping drugs do not prevent
the carbonylation of brain proteins during depletion of the antioxidant glutathione.
Commonly

used

RCS-scavengers

like

aminoguanidine,

pyridoxamine,

methoxylamine, carnosine, taurine and z-histidine hydrazide were unable to
reduce the appearance of protein carbonyls during DEM-induced oxidative stress.
Only hydralazine prevented PCO accumulation at relatively low concentrations,
but the effect is due to its antioxidant properties rather than to its ability to trap
RCS or to react with PCOs directly. This suggests that the majority of proteinassociated carbonyl groups in this oxidative stress paradigm do not derive from
stable LPO products like MDA, acrolein and 4-HNE.

This conclusion was

confirmed by the observation that the amount of MDA-, acrolein- and 4-HNEprotein adducts does not increase in GSH-depleted sections. Thus, this system is
best suited to test the effect of antioxidants on protein carbonylation rather than
to explore the efficacy of new RCS-trapping agents.
Oxidation of polyunsaturated fatty acids gives rise to three major products,
all of which are know to introduce carbonyl groups into proteins. These
compounds include (I) dialdehydes (e.g. MDA), which react with lysine residues
to form carbonyl derivatives; (II) α,β-unsaturated aldehydes (e.g. 4-HNE, 4hydroxy-2-hexenal, acrolein), which undergo a Michael addition reaction with the
ε-amino group of lysine residues, the thiol group of cysteine residues and the
imidazole group of histidine residues; and (III) lipid hydroperoxides, which can
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undergo metal ion-catalyzed decomposition to produce alkoxyl and peroxyl
radicals that can react directly with amino acid residues. Previous work from our
laboratory suggested that lipid hydroperoxide-mediated oxidation is the major
mechanism by which brain proteins (particularly cytoskeletal and membrane
proteins) are carbonylated during acute GSH depletion [9]. In the present study
we have strengthen this conclusion by the finding that none of the classical RCS
scavengers prevent the carbonylation of proteins but more importantly by the
absence of MDA-, 4-HNE- and ACR-protein adducts as measured on western
blots. Lipid hydroperoxide-induced protein carbonylation was initially proposed by
Refsgaard et al., [30], who discovered that metal-catalyzed oxidation of proteins
is greatly enhanced by addition of polyunsaturated fatty acids. These
investigators speculated that alkoxyl radicals, derived from metal-catalyzed
heterolytic cleavage of lipid hydroperoxides, are responsible for the introduction
of carbonyls into proteins by a mechanism that might involve site-specific
interaction with lysine residues. Lipid-derived alkoxyl radicals were found to be
involved also in the oxidation of retinal proteins in diabetes [31], suggesting that
this mechanism is more common than previously thought.
Accumulation of PCOs has been implicated in the etiology and/or
progression of several neurodegenerative disorders such as Alzheimer’s disease
[3], Parkinson’s disease [4], and amyotrophic lateral sclerosis [5]. Our recent
discovery that carbonylation of CNS proteins is augmented in multiple sclerosis
[6, 32] and its animal model experimental allergic encephalomyelitis [33],
suggests

that

this

type

of

protein
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modification

may

play

a

critical

pathophysiological role in inflammatory demyelinating diseases as well.
Therefore, approaches to reduce the extent of protein carbonylation may be
beneficial for treating these disorders. In recent years carbonyl trapping has
received considerable attention as a specific treatment for conditions with severe
carbonyl stress. Carbonyl trapping agents like those tested in this study react
with RCS at a faster rate than do cell macromolecules, thereby ensuring the safe
excretion of drug-carbonyl conjugates. However, this approach is effective only if
protein carbonylation takes place by an indirect mechanism, which does not
seem to be the case during acute depletion of glutathione. Furthermore, aaminoadipic semialdehyde and glutamic semialdehyde, which result from direct
oxidation of lysine, arginine and proline residues, are the major carbonylated
amino acids in CNS proteins during aging and in neurodegenerative disorders
[34, 35]. Thus, in most cases, prevention of protein carbonylation will have to be
achieved with agents that reduce oxidative stress, limit LPO and/or interfere with
the direct oxidation of amino acids. The antihypertensive hydralazine seems to
possess all of these properties since it reduced oxidative stress in intact cells (Fig.
6) and interfered with lipid hydroperoxide-induced protein carbonylation in a cellfree system (Fig. 5B), and there is also evidence that it strongly inhibits LPO [36].
Preliminary studies in our laboratory have shown that administration of
hydralazine reduces CNS damage and decrease neurological symptoms of rats
with acute experimental autoimmune encephalomyelitis, suggesting that this drug
could be potentially useful for treating neuroinflammatory disorders.
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The antioxidant properties of hydralazine have been reported in several
studies and have been attributed to: (1) inhibition of ROS-generating enzymes
such as NADPH oxidase [24], monoamine oxidase [25] and xanthine oxidase
[37], (2) scavenging of superoxide and peroxynitrite [29], and (3) decreased
mitochondrial superoxide production [28, 29]. In this study we ruled out the
participation of NADPH oxidase and monoamine oxidases in the generation of
ROS during GSH depletion, and that of xanthine oxidase was excluded in our
previous study [8]. In addition, we have eliminated the possibility of a direct
reaction of superoxide, hydrogen peroxide and lipid hydroperoxides with
hydralazine. The possibility that hydralazine reduces protein carbonylation by
scavenging peroxynitrite is also unlikely since this oxidant is not produced in this
oxidative stress paradigm as demonstrated by the lack of nitrotyrosine [9].
Furthermore,

addition

of

two

peroxynitrite-scavengers

(uric

acid

and

dimethylthiourea) [8] and a nitric oxide synthetase inhibitor aminoguanidine (this
study) has not effect on protein oxidation in this system. All of these findings,
along with recent observations that hydralazine does not inhibit cytochrome P450 [38], point out to mitochondria as the most likely target of hydralazine in the
DEM-treated brain sections. There is some evidence that hydralazine reduces
the mitochondrial production of superoxide and consequently hydrogen peroxide
[28, 29], and we are currently investigating the molecular mechanism underlying
this effect.

141

Figure A.1 - Chemical structure of the various carbonyl-trapping agents used in this
study. z-, carbobenzoxy- .
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Figure A.2 - Ability of carbonyl scavengers to trap various RCS in a cell-free system.
MDA (36µM), 4-HNE (25µM) and acrolein (100µM) were incubated for 2h at room
temperature in the presence or absence of various carbonyl scavengers (1mM). After
incubation, the amount of unreacted RCS was determined as described under Material
and Methods. Values are expressed as the % of RCS trapped by the scavenger and
represent the mean ± SEM of three separate incubations. The concentration of acrolein
in these experiments was 4-times higher than that of 4-HNE solely because the
sensitivity of the assays for measuring each unsaturated alkenal is different.
Abbreviations: HY, hydralazine; MET, methoxylamine; AG, aminoguanidine; PYR,
pyridoxamine; CAR, carnosine; TAU, taurine; z-HH, z-histidine hydrazide.
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Figure A.3 - Effect of carbonyl scavengers on DEM-induced protein carbonylation. Rat
brain slices were incubated with 10mM DEM in the absence or presence of two different
concentrations of various carbonyl scavengers. After 2h, slices were homogenized in
PEN buffer and aliquots of the homogenate were used to determine the PCOs by
western blot as described under “Material and Methods”. Panel A shows a
representative OxyBlot. The molecular weight markers are: phosphorylase b (97K),
bovine serum albumin (69K), ovalbumin (43K), and carbonic anhydrase (29K). Other
abbreviations are as in Figure 2. Panel B depicts protein carbonylation levels obtained
from western blots and NPSH levels determined spectrophotometrically with 5,5’dithiobis(2-nitrobenzoic) acid. Values are expressed as % of control and represent the
mean ± SEM of 3-4 experiments. Control values for carbonyls and NPSHs are 0.21±0.02
nmol/mg protein and 10.8±0.8 nmol/mg protein, respectively. Asterisks denote those
numbers that are significantly different (p<0.05) from DEM-treated slices.
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Figure A.4 - Detection of RCS-protein adducts in control and GSH-depleted brain slices.
Rat brain slices were incubated in the absence (control) or presence of 10mM DEM.
After 2h, slices were homogenized in PEN buffer and aliquots of the homogenate were
analyzed by western blotting using antibodies against the various RCS as described in
“Material and Methods”.
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Figure A.5 A- Effect of hydralazine on protein-bound carbonyl groups. Oxidized proteins
prepared from DEM-treated brain slices were incubated for 2h in the absence or
presence of two different concentration of hydralazine as described in “Material and
Methods”. PCOs were derivatized with DNPH and analyzed by OxyBlot. The antioxidant
trolox (1mM) was included in some samples to ascertain that further protein oxidation
does not occur during the incubation period. B- Effect of hydralazine on lipid
hydroperoxide-induced protein carbonylation in a cell-free system. Proteins prepared
from control brain slices were incubated for 2h with 15-HpETE in the absence or
presence of two different concentration of hydralazine. After incubation PCOs were
derivatized with DNPH and analyzed by OxyBlot.
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Figure A.6- Effect of increasing concentrations of hydralazine on DEM-induced protein
carbonylation and hydrogen peroxide production. Rat brain slices were incubated with
10mM DEM in the absence or presence of increasing concentrations (0.5-500µM)
hydralazine. After 2h, aliquots from the incubation media were removed and used to
determine H2O2 levels using the FOX assay. Slices were homogenized in PEN buffer
and aliquots of the homogenate were used to determine PCOs by OxyBlot. Values are
expressed as % of control and represent the mean ± SEM of 3-4 experiments. Asterisks
denote values that are significantly different (p<0.05) from DEM-treated slices.
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Figure A.7 A- Effect of hydralazine on hydrogen peroxide and lipid hydroperoxide
stability. Hydrogen peroxide and the lipid hydroperoxide 15-HpETE were incubated in
the absence or presence of two different concentrations of hydralazine. After 2h, residual
peroxide levels were determined with the FOX assay as described under “Material and
Methods”. B- Effect of hydralazine on the stability of pyrogallol-generated superoxide.
Pyrogallol (0.2mM) was incubated in the absence or presence of two different
concentrations of hydralazine, and the rate of autooxidation was determined as
described in “Material and Methods”. Values are expressed as % of control (i.e. without
hydralazine) and represent the mean ± SEM of three experiments. Asterisks denote
values that are significantly different (p<0.05) from controls.
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Figure A.8 - Effect of NADPH oxidase and MAO inhibitors on DEM-induced protein
carbonylation.

Rat brain slices were incubated with 10mM DEM in the absence or

presence of a NADPH oxidase inhibitor (apocynin) or MAO inhibitors (clorgyine,
deprenyl and hydroxylamine). After 2h, slices were homogenized in PEN buffer and
aliquots of the homogenate were used to determine the PCOs by OxyBlot as described
under “Material and Methods”. Panel A shows representative OxyBlots. Panel B depicts
protein carbonylation levels obtained from the western blots. Values are expressed as %
of control and represent the mean ± SEM of 3 experiments. Asterisk denotes the value
that is significantly different (p<0.05) from DEM-treated slices.
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Appendix B

A

B

C

D

E

F

Figure B – Lymphocytes accumulate in cerebellar white matter of EAE mice. EAE
was induced by active immunization with MOG35-55 peptide as described in
Chapter 2. Upper Panels (A-C) and bottom panels (D-F) depict representative
H&E-stained cerebellar sections from control and acute EAE, respectively. PL,
purkinje cell layes; GL, granule cells layer; ML, molecular layer; WM, white
matter. In panel D and E, arrows point to perivenular white matter lesions with
abundant lymphocyte infiltration in the acute EAE. In panel F, arrows point to
lymphocyte accumulation in the acute EAE.
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Appendix C

Figure C – Colocalization of carbonyls and GFAP in the cerebellum of acute EAE
mice. Double immunofluorescence analysis was performed as described in
Chapter 2. Green channel is for GFAP-positive astrocytes while red channel is
for carbonyls. Immunofluorescent images show that cerebellar astrocytes have
normal morphology and show colocalization of GFAP and carbonyl staining in
their distal processes.
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Appendix D

Figure D – Stimulation of astrocytes with LPS. Astrocytes were incubated with
1µg/ml of LPS for 24h as described in Chapter 3. Upper and lower panels depict
representative a double immunofluorescence picture from untreated and LPStreated astrocytes, respectively. GFAP, carbonyls and nuclear (DAPI) staining
are shown in green, red and blue, respectively. Note the profound morphological
changes of the astrocytes after LPS stimulation, including generation of dendritic
processes and enlargement of cell bodies which is typical of activated astrocytes.
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Appendix E

Figure E- The proportion of carbonylated GFAP in cultured astrocytes increases
upon incubation with DEM. C6 cell were initially differentiated into astrocytes as
described in Chapter 3. Astrocytes were then incubated with 10µM DEM. After 24
hours, carbonylated proteins were isolated and probed with antibodies against
GFAP in Chapter 3. Densitometric scans were obtained to calculate the
proportion of the carbonylated GFAP in two conditions (Panel B). Panel A is the
representative blot. Values represent the mean ± SEM of 3 experiments. *p<0.05.
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Appendix F

Figure F.1 The solubility of β-actin in DEM-treated astrocytes is elevated upon
incubation of KCl. C6 cell were initially differentiated into astrocytes and then
treated with DEM. Monomer and polymer were separated as described in
chapter 5. The same volume of monomer and polymer was loaded and probed
with antibodies against β-actin. Densitometric scans were obtained to calculate
the ratio of monomer to polymer in β-actin under various conditions (Panel B).
Panel A is the representative blot. Values represent the mean ± SEM of 3
experiments. *p<0.05. After 2 hours of incubation with 150mM KCl (a ionic
strength close to a physiological medium), the ratio of monomer to polymer in βactin is significantly elevated in the cell lysates from DEM-treated astrocytes,
relative to the control. This data indicated that DEM increased the solubility or
decreased the stability of β-actin under a physiological ionic strength.
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Figure F.2 The solubility of β-tubulin in DEM-treated astrocytes is elevated upon
incubation of KCl. The solubility of β-tubulin to KCl upon DEM treatment is tested
as described in above Figure F.1. Panel A is a representative blot while panel B
shows the statistical results. Values represent the mean ± SEM of 3 experiments.
*p<0.05. Similar to GFAP and β-actin, DEM increased the solubility or decreased
the stability of β-tubulin under a physiological ionic strength.
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Abbreviations
ACR: acrolein
AG: aminoguanidine
BSA: bovine serum albumin
CAR: carnosine
CFA: complete Freund’s adjuvant
CNS: central nervous system
Cox-2: Cyclooxygenase-2,
DNP: 2,4-dinitrophenyl
DPI: days post-immunization
DTT: dithiothreitol
EAE: experimental autoimmune encephalomyelitis
ECL: enhanced chemiluminescence
ER: endoplasmic reticulum
GFAP: glial acidic fibrillary protein
GM: gray matter
GO: glyoxal
GSH: glutathione
HDJ1: DnaJ protein homolog 1
4-HNE: 4-hydroxynonenal
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HY: hydralazine
HSC-71: heat shock cognate-71
IEF: isoelectric focusing
IHC: immunohistochemistry
LLVY-AMC: Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin
LPO: lipid peroxidation
LPS: lipopolysaccharide
MAO: monoamine oxidase
MDA: malondialdehyde
MET: methoxylamine
MGO: methylglyoxal
MOG: myelin oligodendrocyte glycoprotein
MS: multiple sclerosis
PAC: proteasome assembling chaperones
PBS: phosphate-buffered saline
PCO: protein carbonyl
PGPH: peptidylglutamyl-peptide-hydrolizing
POMP: proteasome maturation protein
PYR: pyridoxamine
RCS: reactive carbonyl species
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ROS: reactive oxygen species
SDS: sodium dodecyl sulfate
TAU: taurine
UMP: ubiquitin-mediated proteolysis
WM: white matter
z-HH: z-histidine hydrazide
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